

09/701463

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**REQUEST FOR FILING NATIONAL PHASE OF**  
**PCT APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495**

To: Hon. Commissioner of Patents  
 Washington, D.C. 20231

TRANSMITTAL LETTER TO THE UNITED STATES  
 DESIGNATED/ELECTED OFFICE (DO/EO/US)

Atty Dkt: PM 275915 /P/75085-US  
M# /Client Ref.

From: Pillsbury Madison & Sutro LLP, IP Group:

Date: November 29, 2000

This is a **REQUEST** for **FILING** a PCT/USA National Phase Application based on:

- |  |   |             |            |             |     |       |      |   |           |            |             |     |       |      |
|--|---|-------------|------------|-------------|-----|-------|------|---|-----------|------------|-------------|-----|-------|------|
| 1. International Application<br><br><u>PCT/GB99/01509</u><br><u>↑ country code</u> | 2. International Filing Date<br><br><table border="0"> <tr> <td><u>01</u></td> <td><u>JUN</u></td> <td><u>1999</u></td> </tr> <tr> <td>Day</td> <td>MONTH</td> <td>Year</td> </tr> </table> | <u>01</u>   | <u>JUN</u> | <u>1999</u> | Day | MONTH | Year | 3. Earliest Priority Date Claimed<br><br><table border="0"> <tr> <td><u>29</u></td> <td><u>MAY</u></td> <td><u>1998</u></td> </tr> <tr> <td>Day</td> <td>MONTH</td> <td>Year</td> </tr> </table><br>(use item 2 if no earlier priority) | <u>29</u> | <u>MAY</u> | <u>1998</u> | Day | MONTH | Year |
| <u>01</u>  | <u>JUN</u>  | <u>1999</u> |            |             |     |       |      |   |           |            |             |     |       |      |
| Day  | MONTH   | Year        |            |             |     |       |      |   |           |            |             |     |       |      |
| <u>29</u>  | <u>MAY</u>  | <u>1998</u> |            |             |     |       |      |   |           |            |             |     |       |      |
| Day  | MONTH   | Year        |            |             |     |       |      |   |           |            |             |     |       |      |
4. Measured from the earliest priority date in item 3, this PCT/USA National Phase Application Request is being filed within:
- (a) ☐ 20 months from above item 3 date      (b) ☒ 30 months from above item 3 date,
- (c) Therefore, the due date (unextendable) is November 29, 2000
5. Title of Invention GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF
6. Inventor(s) TISDALE, Michael J. et al

Applicant herewith submits the following under 35 U.S.C. 371 to effect filing:

7. ☒ Please immediately start national examination procedures (35 U.S.C. 371 (f)).
8. ☒ **A copy of the International Application** as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (file if in English but, if in foreign language, file only if not transmitted to PTO by the International Bureau) including:
- a. ☒ Request;
- b. ☒ Abstract;
- c. 52 pgs. Spec. and Claims;
- d. 10 sheet(s) Drawing which are ☐ informal ☒ formal of size ☒ A4 ☐ 11"
9. ☒ **A copy of the International Application has been transmitted by the International Bureau.**
10. **A translation of the International Application** into English (35 U.S.C. 371(c)(2))
- a. ☐ is transmitted herewith including: (1) ☐ Request; (2) ☐ Abstract;
- (3) \_\_\_\_\_ pgs. Spec. and Claims;
- (4) \_\_\_\_\_ sheet(s) Drawing which are:
- ☐ informal ☐ formal of size ☐ A4 ☐ 11"
- b. ☐ is not required, as the application was filed in English.
- c. ☐ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
- d. ☐ Translation verification attached (not required now).

RE: USA National Filing of PCT /GB99/01509

525 Rec'd PCT/PTO 29 NOV 2000

11. ☒ **PLEASE AMEND** the specification before its first line by inserting as a separate paragraph:  
 a. ☒ --This application is the national phase of international application PCT/GB99/01509 filed June 1, 1999 which designated the U.S.--  
 b. ☐ --This application also claims the benefit of U.S. Provisional Application No. 60/\_\_\_\_\_, filed \_\_\_\_\_.--
12. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., **before 18th month from first priority date above in item 3, are transmitted herewith (file only if in English) including:**
13. ☒ PCT Article 19 claim amendments (if any) have been transmitted by the International Bureau
14. ☐ Translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., of **claim amendments made before 18th month, is attached (required by 20th month from the date in item 3 if box 4(a) above is X'd, or 30th month if box 4(b) is X'd, or else amendments will be considered canceled).**
15. **A declaration of the inventor** (35 U.S.C. 371(c)(4))  
 a. ☐ is submitted herewith ☐ Original ☐ Facsimile/Copy  
 b. ☒ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
16. **An International Search Report (ISR):**  
 a. Was prepared by ☒ European Patent Office ☐ Japanese Patent Office ☐ Other  
 b. ☒ has been transmitted by the international Bureau to PTO.  
 c. ☒ copy herewith (2 pg(s).) ☐ plus Annex of family members (\_\_\_\_ pg(s).).
17. **International Preliminary Examination Report (IPER):**  
 a. ☒ has been transmitted (if this letter is filed after 28 months from date in item 3) in English by the International Bureau with Annexes (if any) in original language.  
 b. ☒ copy herewith in English.  
 c.1 ☒ IPER Annex(es) in original language ("Annexes" are amendments made to claims/spec/drawings during Examination) including attached amended:  
 c.2 ☐ Specification/claim pages #47 - 52 claims #1 - 30 Dwg Sheets #  
 d. ☐ Translation of Annex(es) to IPER **(required by 30<sup>th</sup> month due date, or else annexed amendments will be considered canceled).**
18. **Information Disclosure Statement** including:  
 a. ☒ Attached Form PTO-1449 listing documents  
 b. ☐ Attached copies of documents listed on Form PTO-1449  
 c. ☒ A concise explanation of relevance of ISR references is given in the ISR.
19. ☐ **Assignment** document and Cover Sheet for recording are attached. Please mail the recorded assignment document back to the person whose signature, name and address appear at the end of this letter.
20. ☐ Copy of Power to IA agent.
21. ☐ **Drawings** (complete only if 8d or 10a(4) not completed): \_\_\_\_ sheet(s) per set: ☐ 1 set informal; ☐ Formal of size ☐ A4 ☐ 11"
22. Small Entity Status ☐ is **Not** claimed ☒ is claimed (**pre-filing confirmation required**)  
 22(a) \_\_\_\_ (No.) Small Entity Statement(s) enclosed (since 9/8/00 Small Entity Statements(s) not essential to make claim)
23. **Priority** is hereby claimed under 35 U.S.C. 119/365 based on the priority claim and the certified copy, both filed in the International Application during the international stage based on the filing in (country) Great Britain of:
- |     | <u>Application No.</u> | <u>Filing Date</u> |     | <u>Application No.</u> | <u>Filing Date</u> |
|-----|------------------------|--------------------|-----|------------------------|--------------------|
| (1) | <u>9811465.5</u>       | <u>29 May 1998</u> | (2) | _____                  | _____              |
| (3) | _____                  | _____              | (4) | _____                  | _____              |
| (5) | _____                  | _____              | (6) | _____                  | _____              |
- a. ☒ See Form PCT/IB/304 sent to US/DO with copy of priority documents. If copy has not been received, **please proceed promptly to obtain same from the IB.**  
 b. ☐ Copy of Form PCT/IB/304 attached.

RE: USA National Filing of PCT/GB99/01509

525 Rec'd PCT/PTO 29 NOV 2000

24. Attached: Oct. 25, 1999 letter to EPO with attachment (2 pages of a fresh Sequence Listing)

## 25. Preliminary Amendment:

25.5 Per Item 17.c2, cancel original pages #\_\_\_\_\_, claims #\_\_\_\_\_, Drawing Sheets #26. **Calculation of the U.S. National Fee (35 U.S.C. 371 (c)(1)) and other fees is as follows:**Based on amended claim(s) per above item(s) ☐ 12, ☐ 14, ☐ 17, ☐ 25, ☐ 25.5 (hilitte)

Total Effective Claims	minus 20 =	x \$18/\$9 =	\$0	966/967
Independent Claims	minus 3 =	x \$80/\$40 =	\$0	964/965
If any proper (ignore improper) Multiple Dependent claim is present,		add \$270/\$135	+0	968/969

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)): →→ **BASIC FEE REQUIRED, NOW** →→→→A. If country code letters in item 1 are not "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

See item 16 re:

1. Search Report was <u>not</u> prepared by EPO or JPO -----	add \$1000/\$500	960/961
2. Search Report was prepared by EPO or JPO -----	add \$860/\$430	970/971
	<u>+430</u>	

**SKIP B, C, D AND E UNLESS country code letters in item 1 are "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"**

→ ☐ B. If USPTO did not issue both International Search Report (ISR) and (if box 4(b) above is X'd) the International Examination Report (IPER), ----- add \$970/\$485 +0 960/961

(only)  
(one) → ☐ C. If USPTO issued ISR but not IPER (or box 4(a) above is X'd), ----- add \$710/\$355 +0 958/959  
(of)  
(these)  
(4) → ☐ D. If USPTO issued IPER but IPER Sec. V boxes not all 3 YES, ----- add \$690/\$345 +0 956/957  
(boxes)

→ ☐ E. If international preliminary examination fee was paid to USPTO and Rules 492(a)(4) and 496(b) satisfied (IPER Sec. V all 3 boxes YES for all claims), ----- add \$100/\$50 +0 962/963

27. **SUBTOTAL =** \$430

28. If Assignment box 19 above is X'd, add Assignment Recording fee of ----\$40 +0 (581)

29. Attached is a check to cover the ----- **TOTAL FEES** \$430

Our Deposit Account No. 03-3975

Our Order No. 40432

C#

M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 and 492 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed

**Pillsbury Madison & Sutro LLP**  
**Intellectual Property Group**

1100 New York Avenue, NW  
 Ninth Floor  
 Washington, DC 20005-3918  
 Tel: (202) 861-3000  
 Atty/Sec: PNK/sdm

By Atty: **Paul N. Kokulis**Sig: Reg. No. **16773**

Fax: **(202) 822-0944**  
 Tel: **(202) 861-3503**

**NOTE:** File in duplicate with 2 postcard receipts (PAT-103) & attachments.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 040432-0275915

In re patent application of

TISDALE, MICHAEL JOHN et al.

Serial No. 09/701,463

Filed: May 2, 2001

For: GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United


17 SEP 2001

Serial No. 09/701,463

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Aug. 30, 2001  
Date

  
James A. Coburn

**HARBOR CONSULTING**  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021



WILSON GUNN

# Wilson Gunn Skerrett

PATENT AND TRADE MARK ATTORNEYS

Formerly H N & W S Skerrett (Est 1884)

CHARTERED PATENT ATTORNEYS  
EUROPEAN PATENT ATTORNEYS  
REGISTERED TRADE MARK ATTORNEYS  
EUROPEAN TRADE MARK ATTORNEYS

TEL: +44 (0) 121 236 1038  
FAX: +44 (0) 121 233 2875  
E-MAIL: skerrett@ipr.co.uk  
WEB: http://skerrett.co.uk

PATENTS • TRADE MARKS • DESIGNS

CHARLES HOUSE,  
148/9 GREAT CHARLES STREET,  
BIRMINGHAM, B3 3HT,  
ENGLAND.

OUR REF: JNHS/SEB

YOUR REF:

DATE: 25 October, 1999

For the attention of Ms. M. Deleye-Milani

The European Patent Office  
STRAND Program, Directorate Biotechnology (Dir 1212)  
Room S 02 N 24  
P.B. 5818 Patentlaan 2  
NL-2288 EE RIJSWIJK (NL)  
Netherlands.

Dear Sirs

**Re: PCT Patent Application No. PCT/GB99/01509 in the name of  
Tisdale, Michael, John *et al.***

Referring to the Form PCT/ISA/225 mailed 27 September 1999 in connection with the above application, we have now obtained the latest version of the PatentIn software and, as requested, we enclose with a confirmation copy of this letter a fresh sequence listing on paper and in computer readable form (floppy disk) which has been prepared using this software and which we believe conforms to the new WIPO Standard 25.

We confirm on behalf of the Applicants that:

- (a) this fresh computer listing does not go beyond the disclosure in the international application as filed; and
- (b) the information recorded on computer readable form on the enclosed floppy disk data carrier is identical to the accompanying written sequence listing.

We trust that this completes satisfactorily all the residual formalities necessary at this stage.

By way of acknowledgement, PLEASE RETURN THE ENCLOSED FORM EPO 1037 in the enclosed self-addressed envelope provided.

Yours faithfully

Wilson Gunn Skerrett  
Encs

09/701463

525 Rec'd PCT/PTO 29 NOV 2000

BILL DOWNEY, B.Sc. (ENG), EPA, CPA, MITMA, ETMA  
BARRY QUEST, M.A. (Oxon), EPA, CPA, MITMA, ETMA  
MARK GOODWIN, B.Sc., EPA, CPA, MITMA, ETMA

MICHAEL CROFT, EPA, CPA, MITMA, ETMA  
JAMES PEEL, B.A. (Oxon), EPA  
RICHARD HILL, B.Sc., EPA, ETMA  
BRUCE MARSH, M.A. (Cantab), MITMA, ETMA  
IAN MIDDLEMIST, EPA, CPA, MITMA, ETMA  
PATRICIA PHILLIPS, B.Sc., EPA, CPA, MITMA, ETMA  
JAMES ROBESY, M.Sc. (Dunelm)  
SUSAN HARDY, B.A., B.Eng  
PHIL TREEBY, B.Sc  
ROBERT CARLIN, B.Sc

Consultants

JOHN SKERRETT MSc, EPA, CPA, MITMA, ETMA,  
MRSC, C. Chem  
PETER LOW, EPA, CPA

**BY FAX  
CONFIRMATION BY POST**

09/701463-0000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

TISDALE ET AL

Serial No.: 09/701,463

Group Art Unit: Unknown

Filed: November 29, 2000

Examiner: Unknown

Title: GLYCOPROTEINS HAVING LIPID  
MOBILISING PROPERTIES AND  
THERAPEUTIC APPLICATIONS  
THEREOF

May 2, 2001

PRELIMINARY AMENDMENT

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows:

IN THE CLAIMS

Cancel claims 1-30, adding in lieu thereof:

31. (New) A biologically active lipid mobilizing agent for use in therapy which has an apparent molecular mass  $M_r$  as determined by gel exclusion chromatography greater than 6.0 kDa, which is capable of inducing lipolysis in mammalian adipocytes, and which has the properties and characteristics of a Zn- $\alpha_2$ -glycoprotein.

32. (New) A purified biologically active lipid mobilizing agent as claimed in claim 31 for use in therapy which is substantially free of proteolytic activity and which

09/701,463

consists essentially of a glycosylated polypeptide having an apparent relative molecular mass  $M_r$  of about 43 kDa as determined by its electrophoretic mobility when subjected to 15% SDS-PAGE electrophoresis and having homology in amino acid sequence with the amino acid sequence (SEQ ID No: 1) of human plasma Zn- $\alpha_2$ -glycoprotein.

33. (New) A lipid mobilizing agent as claimed in claim 32 which is obtainable by a process that includes sequential steps of subjecting biological material to ion exchange chromatography, exclusion chromatography, and then to hydrophobic interaction chromatography, said biological material being urine from a cancer cachexia patient or an extract of a culture of a MAC16 tumor cell line deposited under the provisions of the Budapest Treaty in the European Collection of Animal Cell Cultures (ECACC) under an Accession No. 89030816.

34. (New) A biologically active lipid mobilizing agent as claimed in claim 31 for therapeutic use which is a glycosylated polypeptide wherein the polypeptide moiety is selected from one of the following groups:

- (a) a polypeptide having the amino acid sequence of a Zn- $\alpha_2$ -glycoprotein;
- (b) a polypeptide which in respect to (a) is deficient in one or more amino acids that do not significantly affect the lipid mobilizing the lipolytic activity;



- (c) a polypeptide in which in respect to (a) one or more amino acids are replaced by a different amino acid or acids that do not significantly affect the lipid mobilizing or lipolytic activity;
- (d) a polypeptide in which in respect to (a) there is incorporated a plurality of additional amino acids which do not interfere with the biological lipolytic activity.

35. (New) A biologically active lipid mobilizing agent for use in therapy as claimed in claim 31 consisting essentially of a glycoprotein that has a polypeptide amino acid sequence homologous with the amino acid sequence (SEQ ID No: 1) of human plasma Zn- $\alpha_2$ -glycoprotein, or with a variant thereof which is modified by minor additions, deletions, or substitutions that do not substantially affect its lipid mobilizing activity in biological systems.

36. (New) A lipid mobilizing agent for use in therapy as claimed in claim 34 or 35 further characterized in that it has an apparent relative molecular mass  $M_r$  of about 43 kDa as determined by its electrophoretic mobility when subjected to 15% SDS-PAGE electrophoresis.

37. (New) A lipid mobilizing agent for use in therapy as claimed in claim 31 wherein its lipid mobilizing properties are destroyed when subjected to digestion with chymotrypsin.

38. (New) A lipid mobilizing agent for use in therapy as claimed in claim 31 wherein it has the potential *in vitro* to stimulate adenylate cyclase activity in a guanine triphosphate (GTP) dependent process upon incubation with murine dipocyte plasma membranes.

39. (New) A lipid mobilizing agent for use in therapy as claimed in claim 31 which has substantially the same immunological properties as human Zn- $\alpha_2$ -glycoprotein.

40. (New) A biologically active lipid mobilizing agent for use in therapy which is capable of inducing lipolysis in mammalian adipocytes characterized, which has an apparent molecular mass  $M_r$  as determined by gel exclusion chromatograph greater than 6.0 kDa, and which is obtainable by subjecting the lipid mobilizing agent claimed in claim 31 to fragmentation by enzymatic degradation.

41. (New) A biologically active lipid mobilizing agent as claimed in claim 40 for use in therapy that is a fragment of a glycoprotein or glycosylated polypeptide which is a component of the lipid mobilizing agent claimed in claim 31 produced by digesting the latter with trypsin.

42. (New) A lipid mobilizing agent for use in therapy as claimed in claim 31 which is substantially free of proteolytic activity.

43. (New) A lipid mobilizing agent for use in therapy as claimed in claim 31 wherein the polypeptide chain of the polypeptide component has an N-terminus blocked by a pyroglutamate residue.

44. (New) A lipid mobilizing agent for use in therapy as claimed in claim 31 wherein the lipid mobilizing activity is destroyed by periodate treatment.

45. (New) A method of isolating and purifying a lipid mobilizing agent having the properties and characteristics of a Zn- $\alpha_2$ -glycoprotein, said method comprising subjecting an extract of a cachexia-inducing tumor or of a culture of a cachexia-inducing tumor cell line, or a sample of urine or other body fluid of a mammal bearing a cachexia-inducing tumor, to a combination of ion exchange, gel filtration size exclusion chromatography, and hydrophobic interaction chromatography, and recovering a single product or molecular species having an apparent relative molecular mass of 43 kDa, as determined by 15% SDS-PAGE electrophoresis, which is substantially free of proteolytic activity.

46. (New) A pharmaceutical composition for use in treating mammals, said composition containing as the active constituent an effective therapeutic amount of a lipid mobilizing agent as claimed in claim 31, together with a pharmaceutically acceptable carrier, diluent or excipient.

47. (New) A pharmaceutical composition as claimed in claim 46 which is an injectable formulation incorporating a carrier in the form of a pharmaceutically acceptable injection vehicle.

48. (New) A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a lipid mobilizing agent as claimed in claim 31.

49. (New) A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a glycoprotein identical to or homologous with human Zn- $\alpha_2$ -glycoprotein, or an effective lipolytically active fragment thereof which has an apparent molecular mass  $M_r$  as determined by gel exclusion chromatography that is greater than 6.0 kDa, substantially free of any proteolytic activity.

50. (New) A diagnostic method for detecting the presence of a tumor in a mammal and/or for monitoring the progress of treatment of such a tumor, said method comprising taking from said mammal a sample of urine, blood serum or other body fluid and testing to detect the presence of and/or to measure the amount therein of Zn- $\alpha_2$ -glycoprotein.

51. (New) A diagnostic method as claimed in claim 50 wherein the testing is carried out by use of a biochemical reagent capable of specifically recognizing and binding to Zn- $\alpha_2$ -glycoprotein.

52. (New) A diagnostic method as claimed in claim 51 wherein the biochemical reagent is a monoclonal or polyclonal antibody.

53. (New) A diagnostic method as claimed in claim 50 which is applied to a sample of urine.

54. (New) A diagnostic kit for carrying out the method of claim 50, said kit comprising a receptacle for receiving the sample of body fluid, a biochemical reagent for detecting Zn- $\alpha_2$ -glycoprotein, and instructions for use of said kit.

55. (New) Use of a lipid mobilizing agent as defined in claim 31 for producing antibodies for use as a diagnostic detecting agent for use in therapy as inhibitors or antagonists to the lipid mobilizing agent causing cachexia in cancer patients.

56. (New) Use of a preparation of antibodies for the manufacture of a medical preparation or medicament for the treatment of cachexia-associated cancer and/or tumors, wherein said antibodies are capable of specifically recognizing and binding to the lipid mobilizing agent claimed in claim 31.

57. (New) Use as claimed in claim 56 of a preparation of antibodies wherein the antibodies are monoclonal antibodies.

58. (New) Use of a lipid mobilizing agent as defined in claim 31 for screening and identifying and/or for carrying out investigations of possible lipolytic activity inhibiting agents having potential as anti-cachectic or anti-tumor therapeutic agents.


59. (New) Use as claimed in claim 58 wherein samples of possible antagonists to, or inhibitors of, the activity of said lipid mobilizing agent are added to preparations of said lipid mobilizing agent, followed by incubation *in vitro* with a preparation of adipocytes and assaying to determine the level of lipolytic activity relative to that of a control sample.

REMARKS

The original claims are being replaced by new claims 31-59.

Respectfully submitted,

Pillsbury Winthrop LLP

By   
Paul N. Kokulis  
Reg. No. 16773

PNK:mh  
1100 New York Avenue, N.W.  
9<sup>th</sup> Floor - East Tower  
Washington, D.C. 20005-3918  
Phone: (202) 861-3503

GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIESAND THERAPEUTIC APPLICATIONS THEREOFField of the Invention

This invention relates to the field of biochemistry and medicine and it is especially concerned with therapeutic applications of certain glycoproteins, including fragments thereof, which exhibit lipid mobilising properties in biological systems. In particular, in one aspect the invention embraces the use of such glycoproteins and fragments thereof for therapeutic treatment of mammals to achieve a weight reduction or for controlling obesity. The invention also relates to the isolation and purification of such glycoproteins from biological material. The invention also relates to the use of such glycoproteins for developing diagnostic agents and inhibitors for therapeutic use.

Background

For convenience, reference publications relating to or mentioned in the following description are numerically labelled and listed in the appended bibliography.

The invention has its origins in research carried out in connection with cancer cachexia. Cancer cachexia is a common condition in many human cancer patients, especially patients with gastrointestinal or lung cancer, and is characterised by progressive weakness, dramatic weight loss and wasting resulting from loss of both adipose tissue and skeletal muscle mass. Previous investigations have indicated that the characteristic loss of weight and body tissues (fat and muscle) cannot usually be explained simply by a reduction of food and water intake, and the effect has been attributed to production by the tumours of catabolic factors that pass into the circulatory system. Both lipolytic and proteolytic activities are involved, and there have been numerous



attempts to isolate and purify the substances that produce these activities, especially lipid mobilising factors responsible for the catabolism of adipose tissue and reduction of carcass fat.

In GB2217330A, for example, the supposed isolation and purification  
 5 was described of lipolytic factors derived from a cachexia-inducing murine tumour designated MAC16 and also from the urine of cachectic cancer patients using chromatographic methods which included at least one stage of gel filtration exclusion chromatography, and results were obtained that suggested there were several related molecular species having an apparent molecular  
 10 weight less than 5000 daltons that were responsible for the lipolytic effect. Severe problems were encountered, however, in attempting to purify the active molecular species to the extent required for use in therapeutic applications and fully to characterise the active material in terms of its chemical constitution. More recently, in 1995, a paper by T. M. McDevitt *et al.*, entitled "Purification  
 15 and characterisation of a lipid-mobilising factor associated with cachexia-inducing tumours in mice and humans", was published in *Cancer Research* 55, 1458-1463 (reference 1), wherein it was reported that a material having an apparent relative molecular mass  $M_r$  of 24kDa had been isolated from both the above-mentioned cachexia-inducing murine tumour MAC16 and from the urine  
 20 of patients with cancer cachexia using an isolation and purification procedure involving a combination of ion exchange, size exclusion and hydrophobic chromatography, and a belief was expressed that this material was a purified form of cancer cachexia lipid mobilising factor. It was subsequently found, however, that this 24kDa material was in fact a proteoglycan which when  
 25 purified to homogeneity would produce a cachectic state in non-tumour bearing mice by inducing catabolism of skeletal muscle protein, as reported by P. Todorov *et al.* 1996, *Nature*, 379, 739-742 (reference 2). Thus, this 24kDa material was a proteolytic factor and it seems that any lipolytic activity had to

be attributed to contamination through co-purification with a separate and distinct lipolytic factor.

#### Summary of the Invention

09204163-1500004

The present invention is based on the subsequent finding that a true  
5 lipolytic or lipid mobilising factor (LMF) produced by the cachexia-inducing murine tumour MAC16 and present also in urine of cancer cachexia patients is in fact a glycoprotein which has an apparent relative molecular weight of about 43kDa as determined by its electrophoretic mobility when subjected to 15% SDS-PAGE electrophoresis and which is the same as, or which is very similar  
10 to and has characteristics in common with, a glycoprotein known as Zn- $\alpha_2$ -glycoprotein. Zn- $\alpha_2$ -glycoprotein has been known since it was found in human blood plasma and first reported in a paper by Burgi and Schmid entitled "Preparation and properties of Zn- $\alpha_2$ -glycoprotein of normal human plasma" (1961) *J. Biol. Chem.* 236, 1066-1074 (reference 3). Although the properties  
15 and physiological function of this material have not been fully determined, the material has been highly purified and characterised in terms of chemical and physical chemical properties. Moreover, the complete amino acid sequence has been reported in a paper entitled "Complete amino acid sequence of human plasma Zn- $\alpha_2$ -glycoprotein and its homology to histocompatibility antigens"  
20 by T. Araki *et al.* (1988) *Proc. Natl. Acad. Sci. U.S.A.*, 85, 679-683 (reference 4) wherein the glycoprotein was shown as consisting of a single polypeptide chain of 276 amino acid residues having three distinct domain structures (A, B and C) and including two disulfide bonds together with N-linked glycans at three glycosylation sites. This amino acid sequence of the polypeptide  
25 component is set out in FIGURE 1 of the accompanying drawings. Although some subsequent publications have indicated that the composition of human Zn- $\alpha_2$ -glycoprotein can vary somewhat when isolated from different body fluids or tissues, all preparations of this material have substantially the same

immunological characteristics. As reported by H. Ueyama, *et al.* (1991) "Cloning and nucleotide sequence of a human Zn- $\alpha_2$ -glycoprotein cDNA and chromosomal assignment of its gene", *Biochem. Biophys. Res. Commun.* 177, 696-703 (reference 5), cDNA of Zn- $\alpha_2$ -glycoprotein has been isolated from human liver and prostate gland libraries, and also the gene has been isolated, as reported by H. Ueyama *et al.* (1993) "Molecular cloning and chromosomal assignment of the gene for human Zn- $\alpha_2$ -glycoprotein", *Biochemistry* 32, 12968-12976 (reference 6). H. Ueyama *et al.* have also described, in *J. Biochem.* (1994) 116, 677-681 (reference 7), studies on Zn- $\alpha_2$ -glycoprotein cDNA's from rat and mouse liver which, together with the glycoprotein expressed by the corresponding mRNA's, have been sequenced and compared with the human material. Although detail differences were found as would be expected from different species, a high degree of amino acid sequence homology was found with over 50% identity with the human counterpart (over 70% identity within domain B of the glycoprotein). Again, common immunological properties between the human, rat and mouse Zn- $\alpha_2$ -glycoproteins have been observed.

The preparation of purified Zn- $\alpha_2$ -glycoprotein from fresh human plasma by a method involving six steps of column chromatography separation has been described by Ohkubo *et al.* in a paper entitled "Purification and characterisation of human plasma Zn- $\alpha_2$ -glycoprotein" (1988) *Prep. Biochem.*, 18, 413-430 (reference 8), of which the content is incorporated herein by reference.

The 43kDa glycoprotein lipolytic or lipid mobilising factor (LMF) isolated and purified in connection with the present invention has been obtained substantially free of any proteolytic factor, both from the cachexia inducing murine tumour MAC16 and from urine of patients with cancer cachexia, using an improved isolation and purification procedure. This procedure has again

involved a combination of ion exchange, exclusion and hydrophobic chromatographic separations but the selectivity of the separations differs from that of chromatographic separations previously used when the 24kDa cachectic factor was isolated, yielding a product that when subjected to 15% SDS-PAGE electrophoresis shows a single band of apparent relative molecular weight of about 43kDa. As already indicated, the lipolytic active material or lipid mobilising factor (LMF) thus isolated, from both the MAC16 tumour and from cancer patients' urine, has been found to be a glycoprotein with characteristics in common with or the same as those of Zn- $\alpha_2$ -glycoprotein isolated from human plasma. Accordingly it has been concluded that this human and mouse LMF are both Zn- $\alpha_2$ -glycoproteins or are very close analogues thereof having a substantial degree of sequence homology and substantially the same biological activity, especially in relation to lipolytic activity with respect to adipocytes. They may therefore be referred to as glycoproteins of the Zn- $\alpha_2$ -glycoprotein type.

In particular, it has been found that:

- a) the human and mouse lipid mobilising factors which have been isolated from the above-mentioned sources both co-migrated with authentic human plasma Zn- $\alpha_2$ -glycoprotein on 15% SDS-PAGE and on 10% non-denaturing gels;
- b) the human and mouse lipid mobilising factors isolated both stained heavily for carbohydrates in the same way as authentic Zn- $\alpha_2$ -glycoprotein;
- c) a polyclonal antibody against human plasma Zn- $\alpha_2$ -glycoprotein was capable of detecting the lipid mobilising activity of the human material and of neutralising this activity *in vitro*;
- d) authentic human plasma Zn- $\alpha_2$ -glycoprotein also shows *in vitro* lipid

mobilising activity and also stimulates adenylate cyclase activity;

- e) the human and mouse lipid mobilising factor and the authentic human Zn- $\alpha_2$ -glycoprotein each show the same chymotrypsin digestion pattern producing similar fragments and loss of activity;
- 5 f) the human lipid mobilising factor isolated is homologous with authentic human plasma Zn- $\alpha_2$ -glycoprotein in amino acid sequence and both have been shown to stimulate production of adenylate cyclase in murine adipocyte plasma membranes in a GTP-dependent process with maximum stimulation at 0.1  $\mu$ M GTP.

10 The term authentic Zn- $\alpha_2$ -glycoprotein is used herein to denote purified Zn- $\alpha_2$ -glycoprotein as prepared from fresh human plasma substantially according to the method described by Ohkubo *et al.* (reference 8). It will be appreciated that in some cases fragments of the isolated lipid mobilising factor or of authentic Zn- $\alpha_2$ -glycoprotein may be produced without loss of the  
 15 lipolytic or lipid mobilising activity, and various additions, deletions or substitutions may be made which also will not substantially affect this activity. In that aspects of the present invention relate to therapeutic applications, it is however important that a high degree of purity should generally be achieved and, in particular, the material should be substantially free of proteolytic  
 20 activity.

In one aspect, the present invention relates to the use in medicine of a glycoprotein lipid mobilising factor as herein defined or a therapeutically effective fragment derived therefrom for treatment of conditions of overweight or obesity in mammals.

25 More particularly, the invention provides a biologically active lipid mobilising agent for use in therapy characterised in that it has the properties and characteristics of a Zn- $\alpha_2$ -glycoprotein, or of a fragment of a Zn- $\alpha_2$ -

glycoprotein that has an apparent molecular mass  $M_r$ , as determined by gel exclusion chromatography, greater than 6.0 kDa. In preferred embodiments this lipid mobilising agent can be defined as being a glycosylated polypeptide wherein the polypeptide moiety is selected from one of the following groups:

- 5 (a) a polypeptide having the amino acid sequence of a Zn- $\alpha_2$ -glycoprotein;
- (b) a polypeptide which in respect to (a) is deficient in one or more amino acids;
- 10 (c) a polypeptide in which in respect to (a) one or more amino acids are replaced by a different amino acid or acids;
- (d) a polypeptide in which in respect to (a) there is a plurality of additional amino acids which do not interfere with the biological lipolytic activity or which may be readily eliminated;
- 15 (e) a polypeptide which is an allelic derivative of a polypeptide according to (a).

Also according to the invention, a biologically active lipid mobilising agent for use in therapy consists essentially of a glycoprotein, or a fragment of said glycoprotein that has an apparent relative molecular mass  $M_r$ , as determined by gel exclusion chromatography, greater than 6 kDa, said  
20 glycoprotein being characterised in that it has a polypeptide amino acid sequence that is homologous with the amino acid sequence (SEQ ID No: 1) of human plasma Zn- $\alpha_2$ -glycoprotein, or with a variant thereof which is modified by additions, deletions, or substitutions that do not substantially affect its lipid mobilising activity in biological systems.

25 In at least some embodiments of the invention the lipid mobilising agent may be further characterised by an apparent relative molecular mass  $M_r$  of about 43kDa as determined by its electrophoretic mobility when subjected

to 15% SDS-PAGE electrophoresis.

Thus, also according to the invention, a purified biologically active lipid mobilising agent for use in therapy is characterised in that it consists essentially of a glycosylated polypeptide comprising a single main component  
5 having an apparent relative molecular mass  $M_r$  of about 43kDa as determined by its electrophoretic mobility when subjected to 15% SDS-PAGE electrophoresis and having homology in amino acid sequence with the amino acid sequence (SEQ ID No: 1) of human plasma Zn- $\alpha_2$ -glycoprotein. This lipid mobilising agent may be further characterised in some embodiments by  
10 the fact that it can be obtained by a process that includes sequential steps of subjecting biological material to ion exchange chromatography, exclusion chromatography, and then to hydrophobic interaction chromatography, wherein said biological material is a body fluid of a cancer cachexia patient or an extract of a culture of a MAC16 tumour cell line deposited in the name of Michael  
15 John Tisdale under the provisions of the Budapest Treaty in the European Collection Of Animal Cell Cultures (ECACC) ) at the Public Health Laboratory Service Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom, under an Accession No. 89030816.

Also, in at least some embodiments, the lipid mobilising agent of the  
20 present invention may be further characterised by one or more of the following features:

- (a) when subjected to digestion with chymotrypsin it is fragmented and its lipid mobilising properties are destroyed;
- (b) it has the potential *in vitro* to stimulate adenylate cyclase activity  
25 in a guanine triphosphate (GTP) dependent process upon incubation with murine adipocyte plasma membranes;
- (c) it has substantially the same immunological properties as human

Zn- $\alpha_2$ -glycoprotein;

- (d) it is an active lipid mobilising fragment of the aforesaid 43kDa glycoprotein or glycosylated polypeptide obtainable by digesting the latter with trypsin;
- 5 (e) it is substantially free of proteolytic activity;
- (f) the polypeptide chain of the polypeptide component has an N-terminus blocked by a pyroglutamate residue;
- (g) the lipid mobilising activity is destroyed by periodate treatment.

The invention also provides pharmaceutical compositions for use in  
 10 treating mammals, e.g. to reduce their weight or control obesity, said compositions containing as the active constituent an effective therapeutic amount of Zn- $\alpha_2$ -glycoprotein or glycoprotein lipid mobilising factor as herein defined, or a lipolytically active fragment thereof, together with a pharmaceutically acceptable carrier, diluent or excipient.

15 The invention also includes the use of a lipid mobilising agent, as herein defined, for the manufacture of a medicament useful in human medicine for treating conditions of overweight or obesity.

Thus, the invention further provides a glycoprotein lipid mobilising factor having properties and characteristics of Zn- $\alpha_2$ -glycoprotein, especially  
 20 human Zn- $\alpha_2$ -glycoprotein, for use in the production of a medicament effective in treating conditions of overweight or obesity. Such a medicament may also be useful for stimulating muscle development and increasing muscle mass.

The invention also provides a method of isolating and purifying lipolytically active glycoprotein or lipid mobilising agent having the properties  
 25 and characteristics of a Zn- $\alpha_2$ -glycoprotein, i.e. a glycoprotein of the Zn- $\alpha_2$ -glycoprotein type, said method comprising subjecting an extract of a cachexia-inducing tumour or of a culture of a cachexia-inducing tumour cell line, or a



sample of urine or other body fluid from a mammal bearing a cachexia-inducing tumour, to a combination of ion exchange, gel filtration or size exclusion chromatography, and hydrophobic interaction chromatography, yielding a single product or molecular species having an apparent molecular weight or relative molecular mass of 43kDa, as determined by 15% SDS-PAGE electrophoresis, which is substantially free of proteolytic activity.

The invention also includes a method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal a therapeutically effective dosage of a lipid mobilising agent as herein defined. In general, this will be provided by a glycoprotein identical to or homologous with a human Zn- $\alpha_2$ -glycoprotein, or an effective fragment thereof, substantially free of any proteolytic activity.

The lipid mobilising glycoprotein or Zn- $\alpha_2$ -glycoprotein may be administered as an injectable formulation incorporating a carrier in the form of a pharmaceutically acceptable injection vehicle.

The glycoprotein or fragment thereof used in these therapeutic applications may further be produced by recombinant DNA techniques such as are well known in the art, based possibly on the known cDNA sequence for Zn- $\alpha_2$ -glycoprotein which has been published for example in reference 7.

The invention also includes a method for detecting the presence of a cachexia inducing tumour, and/or for monitoring changes in such a tumour, e.g. during the course of antitumour therapy, said method comprising taking a sample of urine, blood serum or other body fluid, and testing to detect the presence of and/or to measure the amount therein of the lipid mobilising agent herein defined or of Zn- $\alpha_2$ -glycoprotein. In carrying out this method, a monoclonal or polyclonal antibody against Zn- $\alpha_2$ -glycoprotein or other biochemical reagent may be used as a diagnostic detecting agent, as hereinafter described.

The purified lipid mobilising factor or Zn- $\alpha_2$ -glycoprotein of this invention may also be used for producing antibodies, either monoclonal or polyclonal antibodies but preferably monoclonal antibodies, which can then be used as diagnostic detecting agents as mentioned above, or which can be used  
5 in therapy as inhibitors or antagonists to the lipolytic agent(s) causing cachexia in cancer patients.

The antibodies referred to may be, for example, whole antibodies or fragments thereof. Particular antibody fragments may include those obtained by proteolytic cleavage of whole antibodies, such as F(ab')<sub>2</sub>, Fab' or Fab  
10 fragments; or fragments obtained by recombinant DNA techniques, for example Fv fragments (as described in International Patent Specification No. WO 89/02465. In a further aspect of the invention, the use of one or more of such antibodies is envisaged for the manufacture of a medical preparation or medicament for the treatment of cachexia-associated cancer and/or tumours.

The antibody or antibody fragment may in general belong to any immunoglobulin class. Thus, for example, it may be an immunoglobulin M (IgM) antibody or, in particular, an immunoglobulin G (IgG) antibody. The antibody or fragment may be of animal, for example mammalian, origin and may be for example of murine, rat or human origin. It may be a natural  
15 antibody or a fragment thereof, or, if desired, a recombinant antibody or antibody fragment, i.e. an antibody or antibody fragment which has been produced using recombinant DNA techniques.  
20

Particular recombinant antibodies or antibody fragments include, (1) those having an antigen binding site at least part of which is derived from a  
25 different antibody, for example those in which the hypervariable or complementary determining regions of one antibody have been grafted into the variable framework regions of a second, different antibody (as described in European Patent Specification No. 239400); (2) recombinant antibodies or

fragments wherein non-Fv sequences have been substituted by non-Fv sequences from other, different, antibodies (as described in European Patent Specifications Nos. 171496, 172494 and 194276); or (3) recombinant antibodies or fragments possessing substantially the structure of a natural immunoglobulin but wherein the hinge region has a different number of cysteine residues from that found in the natural immunoglobulin, or wherein one or more cysteine residues in a surface pocket of the recombinant antibody or fragment is in the place of another amino acid residue present in the natural immunoglobulin (as described in International Patent Specifications Nos. WO 89/01974 and WO 89/01782 respectively).

As indicated, the antibody or antibody fragment may be polyclonal, but is preferably of monoclonal origin. It may be polyspecific, but is preferably monospecific for the lipolytic material or Zn- $\alpha_2$ -glycoprotein of the invention.

Whole antibodies may be prepared using well-known immunological techniques employing the purified active lipolytic material or Zn- $\alpha_2$ -glycoprotein from any source as antigen. Thus, for example, any suitable host may be injected with the lipolytic material and the serum collected to yield the desired polyclonal antibody after appropriate purification and/or concentration (for example, by affinity chromatography using immobilised lipolytic material as the affinity medium). Alternatively, splenocytes or lymphocytes may be recovered from the injected host and immortalised using for example the method of Kohler *et al.*, (1976), *Eur. J. Immuno*, 6, 511, (reference 9) the resulting cells being segregated to obtain a single genetic line producing monoclonal antibodies in accordance with conventional practice.

If in the above methods the lipolytic material is of a size that does not elicit a suitable immune response in the host, even though it may be antigenic and capable of binding to specific antibodies, it may be preferable covalently to link the material to a large carrier molecule which is itself immunogenic, and to

+use the resulting conjugate compound as the antigen, again in accordance with conventional practice [see for example, D.M. Weir, in "*Handbook of Experimental Immunology*", 3, 2<sup>nd</sup> ed. pp A2.10-A2.11. *Blackwell Scientific Publications, Oxford*, 1973, (reference 10); and M.Z. Atassi and A.F.S.A. Habeeb, in "*Immuno-chemistry of Proteins*" (M.Z. Atassi, ed), 2, pp 177-264, Plenum, New York, 1977 (reference 11)].

Antibody fragments may be produced using conventional techniques, for example by enzymatic digestion, e.g. with pepsin [Lanoyi and Nisonoff, (1983) *J. Immunol. Meth.*, 56, 235, (reference 12)]. Where it is desired to produce recombinant antibodies according to the invention these may be produced using for example the general methods described in the above-mentioned patent specifications.

The invention also extends to diagnostic kits for carrying out the diagnostic methods referred to, such kits comprising a receptacle for receiving the sample of body fluid, a biochemical reagent for detecting said lipid mobilising agent or Zn- $\alpha$ 2-glycoprotein, and instructions for use of the kit.

The lipid mobilising agent of the present invention may also be used for screening and identifying and/or for carrying out investigations of possible lipolytic activity inhibiting agents having potential as anti-cachectic or antitumour therapeutic agents. This screening may be carried out by adding samples of possible antagonists to, or inhibitors of, the activity of said lipid mobilising agent to preparations of said lipid mobilising agent, followed by incubation *in vitro* with a preparation of adipocytes and assaying to determine the level of lipolytic activity relative to that of a control sample.

## MORE DETAILED DESCRIPTION

Examples hereinafter presented illustrate in more detail at least some aspects of the invention and its development. There first follows, however, an outline or summary of some of the materials, methods and techniques which  
5 have generally been used in the development of the invention and in the illustrative examples unless subsequently stated otherwise.

### Animals:

Pure strain NMRI and ob/ob mice were bred from existing in-house colonies; male BKW mice (40-50g) were purchased from Banting and  
10 Kingman, Hull, United Kingdom. These animals were transplanted with fragments of the MAC16 tumour into the flanks, by means of a trocar as described by S.A. Beck *et al.* (1987) "Production of lipolytic and proteolytic factors by a murine tumour-producing cachexia in the host" *Cancer Res.* 47, 5919-5923 (reference 14). The solid tumours were excised from the mice when  
15 the weight loss reached 25%.

### Subjects:

Urine was collected from patients having unresectable pancreatic cancer with established weight loss ranging between 1.3 and 10kg/month. These patients were not receiving therapy at the time of urine collection.  
20 Samples of urine were stored frozen at -20°C in the absence of preservatives prior to the purification.

### Chromatography Apparatus and Materials:

Sephadex™ Mono Q HR 5/5 anionic exchange resin, Superose™ 12H 10/30 gel exclusion and Resource™ Iso hydrophobic chromatography columns  
25 were purchased from Pharmacia Biotech, St. Albans, United Kingdom. An Aquapore™ AX-300 DEAE-cellulose column was supplied by Applied Biosystems, California. Rainbow™ protein molecular weight markers, ECL

Western blotting system and Hyperfilm™-ECL autoradiography film were from Nycomed Amersham Plc, United Kingdom.

Other Materials:

Other materials included a DIG glycan detection kit from Boehringer Mannheim GmbH, Germany, protein A peroxidase conjugate from Sigma, Dorset, United Kingdom, nitrocellulose membranes from Hoefer Scientific Instruments, California and Amicon filters (YM10) from Amicon Ltd., Stonehouse, Gloucestershire, United Kingdom. Also used were “Mini-Message Maker” and spot-on kits purchased from Rand D Systems, Abingdon, United Kingdom and Superscript™ TH11 RT reverse transcriptase from Gibco BRL, Paisley, Scotland. Oligonucleotides were synthesized by Oswell, Southampton, United Kingdom.

DEAE Cellulose Column Chromatography:

In a typical example of using this technique, homogenate containing active lipid mobilising factor (LMF) would be centrifuged and the supernatant would be fractionated by anion exchange chromatography using a DEAE-cellulose column and eluting under a salt gradient. The DEAE-cellulose column would first be equilibrated with buffer solution at the required pH before applying a sample of the material to be fractionated. Thereafter, material would be eluted from the column using a linear salt gradient, e.g. 0 to 0.2M NaCl, in the same buffer. The effluent from the column would be collected in small volume fractions, e.g. 5ml fractions, and the lipolytic activity of each fraction would be measured by the lipolytic assay technique referred to below.

Use of a DEAE cellulose column with elution under a salt gradient is a procedure at least potentially useful as a preliminary separation stage, but it can be especially useful for obtaining further fractionation after a stage of gel

filtration exclusion chromatography and prior to a final or later purification stage of hydrophobic interaction chromatography. As hereinafter described, in a subsequent stage or stages the latter may be carried out employing selected hydrophobic chromatography columns such as Resource™ Iso columns in  
 5 conjunction with high performance liquid chromatography (HPLC) methods.

#### Serum metabolite determinations

Non-esterified fatty acids (NEFA) were determined using a Wako-ASC-ACOD kit (Wako Chemical GmbH, Neuss, Germany). Triglycerides were determined using a Triglyceride kit (Sigma Chemical Co., Poole, United  
 10 Kingdom) and 3-hydroxybutyrate by a quantitative enzymatic determination kit (Sigma). Glucose was measured using a glucose analyser (Beckman, Irvine, CA) and glycerol was determined enzymatically using the method of Wieland as described in "Methods of Enzymatic Analysis" (Ed. Bergmeyer, H.U.) Vol. 3, pp1404-1409, published by Academic Press, London (1974) (reference 13).

#### 15 Lipolytic assay

Single cell suspensions of white adipocytes were prepared from finely minced epididymal fat pads of male BKW mice using collagenase digestion, substantially as described by S.A. Beck *et al.* (see above-mentioned reference 14). Samples to be assayed were incubated with  $10^5 - 2 \times 10^5$  adipocytes  
 20 (determined by means of a haemocytometer) for 2h at 37°C in 1ml of Krebs-Ringer bicarbonate buffer, pH 7.2. The concentration of glycerol released was determined enzymatically by the method of Wieland as referred to above (see also GB2217330A). Control samples containing adipocytes alone were analyzed to determine the spontaneous glycerol release. Lipid mobilizing  
 25 activity was expressed as  $\mu\text{mol}$  glycerol released/ $10^5$  adipocytes/2h.

#### Isolation of Human Omental Adipocytes

Human omental adipose tissue was removed under general anaesthesia

and transported immediately to the laboratory. Fragments of tissue (roughly equivalent in size to a pair of murine epididymal fat pads) were digested to produce a single cell suspension of adipocytes by incubation at 37°C for 30min in a 1ml aliquot of Krebs-Ringer bicarbonate buffer supplemented with 4%  
 5 bovine serum albumin, 1g/l glucose and 1.5mg/ml collagenase, using for this purpose a shaking water bath.

#### Isolation of mouse adipocyte plasma membranes

In a typical procedure white adipocytes were isolated from mouse epididymal fat pads as referred to above except that the cells were washed in  
 10 250mM sucrose, 2mM ethyleneglycol bis( $\beta$ -aminoethylether)-*N,N,N',N'* (EGTA), 10mM Tris-HCl (pH 7.4). Adipocytes were resuspended in 20ml of the above buffer and homogenised by aspirating through a Swinny filter at least 10 times. The cell homogenate was then centrifuged at 300g for 5min, the fat cake removed from the surface and the remaining pellet and infranant  
 15 transferred to clean tubes. These were centrifuged at 30,000g for 1h at 4°C and the membrane pellet formed was resuspended in the sucrose buffer (200 to 400 $\mu$ l). Plasma membranes were separated from other organelle membranes on a self-forming gradient of Percoll™ colloidal silica particles. The constituents were 250mM sucrose, 2mM EGTA, 10mM Tris-HCl, pH 7.4; Percoll™; and  
 20 2M sucrose, 8mM EGTA, 80mM Tris-HCl, pH 7.4, mixed in a ratio of 32:7:1 together with the membrane suspension (in a total volume of 8ml). This mixture was centrifuged at 10,000g for 30min at 4°C. The gradient was fractionated into 0.75ml portions and each portion was assayed for the presence of succinate dehydrogenase, NADH-cytochrome c reductase, lactate  
 25 dehydrogenase and 5'-nucleotidase to locate the plasma membrane fraction. The membrane fractions were resuspended in 150mM NaCl, 1mM EGTA, 10mM Tris-HCl, pH 7.4 and centrifuged at 10,000g at 4°C for 2 min. The process was repeated twice. The washed plasma membranes were then diluted



in 10mM Tris-HCl, pH 7.4, 250mM sucrose, 2mM EGTA and 4 $\mu$ M phenylmethylsulfonyl fluoride (PMSF) at 1-2mg/ml, snap frozen in liquid nitrogen and stored at -70°C until use.

#### Adenylate cyclase assay

5           An adenylate cyclase assay used was based on that developed by Salomon *et al.* (reference 16). Briefly, water (negative control), isoprenaline (positive control) or LMF was added to an assay mix (final volume 100 $\mu$ l) containing 25mM Tris-HCl, pH 7.5, 5mM MgCl<sub>2</sub>, GTP (guanine triphosphate), 8mM creatine phosphate, 16 units/ml creatine phosphokinase, 1mM 3-isobutyl-  
10 1-methylxanthine and 1mM [ $\alpha$ -<sup>32</sup>P] ATP (sp. act. 20mCi/mmol). Preincubation was at 30°C for 5min and the reaction was initiated by the addition of plasma membrane (typically 50 $\mu$ g protein). After 10min at 30°C the reaction was terminated by the addition of 100 $\mu$ l of a solution containing 2% sodium dodecylsulphate, 40mM ATP and 1.4mM cyclic AMP. In order to  
15 determine recovery of cyclic AMP [8-<sup>3</sup>H] adenosine 3',5'-cyclic phosphate (1 $\mu$ Ci in 50 $\mu$ l of water) was added to each tube. Background binding was determined by running samples without [ $\alpha$ -<sup>32</sup>P] ATP and sample controls were set up without plasma membranes.

20           Samples containing labelled nucleotides were diluted to 1ml with water and loaded onto Dowex™ 50W8-400 ion-exchange columns primed with 10ml of water. After washing twice with 1ml of water the cyclic AMP was eluted with 3ml of water into polypropylene tubes containing 200 $\mu$ l of 1.5M imidazole, pH 7.2. The samples were then applied to Alumina WN-3 columns (previously washed with 8ml of 0.1M imidazole, pH 7.5) and the eluate  
25 collected directly into scintillation vials containing the scintillation fluid supplied under the Trade Mark Optiphase HiSafe 3. A further 1ml of 0.1M imidazole was added to the columns and the eluate was combined with the run through. The radioactivity was determined using a Tri-carb™ 2000A

scintillation analyser.

### Zn- $\alpha_2$ -glycoprotein

Samples of Zn- $\alpha_2$ -glycoprotein were used in identifying the lipid mobilizing factor isolated. The Zn- $\alpha_2$ -glycoprotein used was purified approximately 670-fold from fresh human plasma using a combination of DEAE-Sephadex A-50, DEAE-Sephacel, Zn-chelate Sepharose 6B, Phenyl-Sepharose, Sephacryl S-300 and HA-Ultrogel column chromatography substantially as described by Ohkubo *et al.* "Purification and characterisation of human plasma Zn- $\alpha_2$ -glycoprotein" (1988) *Prep. Biochem* **18**, 413-430 (reference 8), of which the content is incorporated herein by reference.

### Gel Electrophoresis

Gels were prepared according to the method of Laemmli (reference 15) and generally consisted of a 5% stacking gel and a 15% SDS-PAGE resolving gel (denaturing or reducing conditions) or a 10% SDS-PAGE resolving gel (non-denaturing or non-reducing conditions). Samples were loaded at 1-5  $\mu$ g/lane. Bands were visualised by staining either with Coomassie brilliant blue R-250 or by silver. Samples were prepared for reducing conditions by heating for 5 min at 100°C in 0.0625M Tris-HCl, pH 6.8, 10% glycerol, 1% SDS, 0.01% bromophenol blue and 5% 2-mercaptoethanol.

For immunoblotting, the gels were transferred to nitrocellulose membranes which had been blocked with 5% Marvel in 0.15% Tween 20 in PBS at 4°C overnight. The nitrocellulose membranes were washed once for 15 min and twice for 5 min in 0.5% Tween 20 in phosphate buffered saline (PBS) at room temperature. Immunodetection was carried out using polyclonal antiserum for Zn- $\alpha_2$ -glycoprotein (10  $\mu$ g/ml) prepared as described by Ohkubo *et al.* (see reference 8 mentioned above) in 1.5% Marvel, 0.15% Tween 20 in PBS for 1 hour at room temperature. After being washed three times as above

the filters were incubated for 1 hour with protein A peroxidase conjugate at a 1:500-fold dilution followed by one 15 min wash and four 5 min washes with 0.5% Tween 20 in PBS. The ECL detection system was used, and the blots were suspended in equal volumes of detection reagents 1 and 2 using 0.125 ml/cm<sup>2</sup> for 1 min at room temperature and then wrapped in Saran Wrap™. The blots were exposed to autoradiography film (Hyperfilm™ ECL) for 30 seconds to 10 min depending on the amount of target protein.

#### BRIEF DESCRIPTION OF THE DRAWINGS

In connection with the description of the invention and illustrative examples detailed below reference should be made to the accompanying drawings in which:

FIGURE 1 is a diagram of the complete amino acid sequence (SEQ ID No: 1) of the human plasma Zn- $\alpha_2$ -glycoprotein, as published by T. Araki *et al.* (1988) "Complete amino acid sequence of human plasma Zn- $\alpha_2$ -glycoprotein and its homology to histocompatibility antigens" (reference 4);

FIGURE 2 is a diagram of the lipolytic activity distribution pattern and protein content of fractions obtained in a stage of anion exchange chromatography, using an Aquapore™ AX-300 DEAE column, applied to the active lipolytic fractions obtained from a preliminary stage of gel filtration chromatographic separation on a Q-Sepharose column as hereinafter described in Example 2;

FIGURE 3 is a diagram of the lipolytic activity distribution pattern and protein content of fractions obtained by a further stage of HPLC hydrophobic interaction chromatography on a Resource™ Iso hydrophobic column of those fractions from the Aquapore™ AX-300 DEAE fractionation stage illustrated in FIGURE 2 that contained the major activity peak;

FIGURE 4 shows the electrophoresis patterns produced by human and mouse LMF isolated and purified as in Examples 1 and 2, and also the pattern

produced by human plasma Zn- $\alpha_2$ -glycoprotein following 15% SDS-PAGE;

FIGURE 5 is a diagram similar to FIGURE 4 but shows the banding pattern obtained for human plasma Zn- $\alpha_2$ -glycoprotein (lane 2) and for human LMF (lane 3) as prepared from Example 2;

- 5 FIGURE 6 shows further banding patterns obtained with SDS-PAGE used for detecting carbohydrate as is also hereinafter described;

FIGURE 7 shows a Western blot banding pattern produced by human plasma Zn- $\alpha_2$ -glycoprotein (lane 1) and by human LMF (lane 2) after 15% SDS-PAGE using a polyclonal antibody to Zn- $\alpha_2$ -glycoprotein;

- 10 FIGURE 8 is a further electrophoresis banding pattern obtained following experiments made to determine the effect of  $\alpha$ -chymotrypsin on human plasma Zn- $\alpha_2$ -glycoprotein and on the isolated and purified human LMF;

- 15 FIGURE 9 is a bar chart diagram comparing the stimulation of lipolysis in freshly isolated murine epididymal adipocytes by human LMF (A) and by human Zn- $\alpha_2$ -glycoprotein (B), the results being expressed as a mean  $\pm$  SEM Values for glycerol release from fat cells alone have been subtracted from the values given, and the data is representative of three separate experiments. Differences from controls were determined by Student's t-test and are indicated as \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$  and \*\*\*  $p \leq 0.005$ .

- 20 FIGURE 10 is a diagram showing change in body weight of ex-breeder male NMRI mice (30-40g) produced by intravenous (iv) administration of LMF (8 $\mu$ g) isolated from human urine as described in Example 2 (o) and of control mice administered PBS by iv injection (x).

- 25 FIGURE 11 is a diagram similar to FIGURE 10 showing change in body weight of ob/ob mice produced by iv administration of LMF (35 $\mu$ g) (o) isolated from human urine as described in Example 2 and of control mice (x) administered PBS by iv injection. LMF was injected at times 0, 16, 24, 40, 48,

64, 72, 90, 96, 113, 120, 137 and 144h; PBS was injected at the same time points. The animals were killed 160h after the first injection. Results are expressed as mean  $\pm$  SEM for 5 animals per group.

FIGURE 12 shows graphs illustrating the effect of trypsin digestion for  
5 different time periods (2hrs, 4hrs and 8hrs) on the biological activity of the  
43kDa LMF.

**EXAMPLE 1****Isolation and Purification of lipid mobilizing factor from Murine Adenocarcinoma MAC16.**

The procedure followed in this example is summarised in Table 1 at the end of the present description and involved the initial purification of the lipid mobilising factor (LMF) from the MAC16 tumour using a preliminary batch extraction on DEAE-cellulose and/or possibly protein precipitation by ammonium sulphate, followed by anion exchange chromatography on a Sepharose™ Mono Q HR 5/5 anion exchange column and size exclusion on Superose 12.

More particularly, solid tumours were excised from mice with weight loss and homogenized in 10mM Tris-HCl (pH 8.0) containing 0.5mM phenylmethylsulfonyl fluoride (PMSF), 0.5mM EGTA, and 1mM DTT at a concentration of 5ml/g of tumour. Debris was removed from the homogenate by low-speed centrifugation (4000 rpm for 15 min in a bench-top centrifuge). When using ammonium sulfate precipitation, ammonium sulphate solution (38% w/v) was slowly added at this stage to the supernatant with stirring at 4°C and the precipitate was removed by centrifugation (4500 rpm for 20 min). The supernatant was then concentrated using an Amicon filtration cell containing a membrane filter with a molecular weight cut-off of  $M_r$  10,000 against original homogenisation buffer.

Batch extraction on DEAE-cellulose at this stage this was conveniently carried out substantially as described by T.M. McDevitt *et al.* "Purification and characterization of a lipid-mobilizing factor associated with cachexia inducing tumours in mice and humans" *Cancer Res.*, (1995) 55, 1458-1463 (reference 1).

The next step was anion exchange chromatography using Q-Sepharose.

The column used was the Mono Q HR 5/5 anion exchange column which has a protein capacity of 20-50mg protein. The column was equilibrated prior to use with homogenising buffer, and the sample was loaded after centrifugation for 10 min at 1300 rpm as a 500- $\mu$ l injection. After an initial wash, active material  
5 was eluted under a 0-0.2 M NaCl gradient. The presence of the active fractions was determined using the measurement of glycerol release from murine adipocytes in accordance with the lipolytic bioassay previously referred to. The active fractions were concentrated using an Amicon filtration cell and dissolved in 0.5ml of 50mM phosphate (pH 8.0) containing 0.3 M NaCl, 0.5mM PMSF,  
10 0.5mM EGTA, and 1mM DTT prior to FPLC Superose™ (or Superdex™) chromatography. The column used in carrying out this specific example was the Superose 12 prepacked 10/30 gel exclusion column, which was equilibrated with the above buffer for 2 hours at 0.25 ml/min, after which the sample was loaded as a 200- $\mu$ l injection. Thirty 1.0ml fractions were collected, and the  
15 lipid-mobilising activity was detected by the aforesaid lipolytic bioassay.

Up to this point the procedure has followed closely that described by McDevitt *et al.* in previously mentioned reference 9, but whereas the latter then continued with a final step of HPLC using a C<sub>8</sub> hydrophobic column and an acetonitrile/TFA gradient, in the present case the active fractions from the  
20 Superose column were further fractionated using an Aquapore™ AX-300 DEAE-cellulose column coupled to an HPLC system and eluting under a gradient from 0 to 0.3M NaCl before carrying out the final HPLC hydrophobic chromatography stage using the hydrophobic column marketed under the Trade Mark "Resource Iso". This modification led to the isolation of a much more  
25 stable bioactive product different from the products previously isolated.

In this last-mentioned stage of HPLC using the Aquapore™ AX-300 DEAE-cellulose column, typically the flow rate was 0.2ml min<sup>-1</sup> with a solvent system composed of component A (10mM Na-phosphate pH 5.3) and

component B (10mM Na-phosphate pH 5.3 + 0.3 M NaCl). All solvents were degassed prior to use. In one particular separation the gradient was changed according to the following protocol: 10 min 0%B, 40 minutes 100%B, 50 minutes 100%B, and 60 minutes 0%B. Absorbance ( $A_{214}$ ) was monitored at 214nm to determine protein content. Each of the eluted peaks was collected as a separate fraction. The salt in these fractions from the DEAE-cellulose column was removed by ultrafiltration through a Microcon™ microconcentrator containing a membrane filter having a molecular weight cut-off of  $M_r$  10,000 (Amicon) against deionized water containing 0.5mM PMSF, 0.5mM EGTA, 1mM DTT. Again, the lipid-mobilising activity was detected by the lipolytic bioassay, and active fractions were concentrated using a Microcon™ microconcentrator against 50mM phosphate buffer (pH 7.0) containing 1.5M ammonium sulfate prior to HPLC hydrophobic chromatography.

In the HPLC final step of this purification procedure using the hydrophobic column Resource™<sub>iso</sub>, 1ml (Pharmacia Biotech), the flow rate was 1ml/min<sup>-1</sup> with a solvent system C (50mM phosphate pH 7.0 + 1.5 M ammonium sulfate) and D (50mM phosphate pH 7.0). All solvents were degassed prior to use. A typical gradient protocol was 5 minutes 0%D, 20 minutes 100%D, 30 minutes 100%D, and 35 minutes 0%D. Again, absorbance ( $A_{214}$ ) was monitored at 214nm to determine protein content, and each of the eluted peaks was collected as a separate fraction. After removing the salt by ultrafiltration (through a Microcon™ microconcentrator against deionized water containing 0.5mM PMSF, 0.5mM EGTA, and 1mM DTT) the lipid-mobilising activity was detected by the lipolytic bioassay as before.

## **EXAMPLE 2**

### **Isolation and Purification of a Lipid-mobilising Factor from urine of cachectic patients**

Urine from a cancer patient with weight loss was fractionated



according to a scheme similar to that used for the MAC16 tumour, although fewer steps were required to get a pure product (see summary in Table 2 at the end of the present description) because of the lower protein content of urine. In the first stage the urine was subjected to precipitation with 80%  $(\text{NH}_4)_2\text{SO}_4$  and the precipitate was dialysed against 10mM Tris-HCl (pH 8.0) containing 0.5mM PMSF, 0.5mM EGTA and 10mM DTT using an Amicon filtration cell containing a membrane filter having a molecular weight cut-off of  $M_r$  10,000. The urine concentrate was then fractionated by anion exchange chromatography using Q-Sepharose, followed by HPLC using an Aquapore™ AX-300 (30x21mm) DEAE-cellulose column (flow rate of  $0.2\text{ml min}^{-1}$  with 10mM phosphate buffer at pH 5.3) under a linear 0-0.4M NaCl gradient which was run for 30 minutes. The protein content and the bioactivity of the fractions were determined respectively by measuring the absorbance  $A_{214}$  and by measuring the release of glycerol from epididymal adipocytes using the standard lipolytic assay as previously described. The results of typical fractionation at this DEAE-cellulose fractionation stage are illustrated in the diagram of FIGURE 2.

There then followed a final stage of hydrophobic interaction chromatography using the hydrophobic column Resource™ Iso (6.4x30mm) to fractionate the active material obtained from the DEAE-cellulose column, substantially as described in connection with Example 1. In this final stage, typically the starting buffer was 50mM phosphate, pH 7.0, containing 1.5M  $(\text{NH}_4)_2\text{SO}_4$  and the column was run under a linear gradient of the elution buffer (50mM phosphate, pH 7.0, with a flow rate of  $1\text{ml min}^{-1}$ ). The diagram of FIGURE 3 illustrates the results in one example of this final stage of hydrophobic chromatography.

Upon repeating the procedure of Example 2 on a range of cancer patients and normal subjects it was found that although cancer patients with

weight loss generally show the presence of this LMF in the urine it was absent from the urine of cancer patients without weight loss and from normal subjects, as demonstrated for example in Table 3 at the end of the present description.

### **Properties and Identity of the Lipid-Mobilising Factor (LMF) as isolated in**

#### **5 Examples 1 and 2**

##### **A. Molecular Weight**

When subjected to 15% SDS-PAGE, both the human and mouse LMF, isolated and purified as described, showed a single protein band of an apparent relative molecular mass of  $M_r$  43kDa. This is illustrated in FIGURE 4 in which  
 10 lane 1 shows molecular weight markers, lanes 3 and 4 show the banding pattern obtained with the human LMF and lane 5 shows the banding pattern obtained with the mouse LMF.

When electrophoresed on 10% non-denaturing PAGE the purified human and mouse LMF both showed an apparent molecular weight of 84kDa,  
 15 the banding pattern obtained using the human LMF being shown in lane 3 of FIGURE 5 wherein lane 1 again shows molecular weight markers.

##### **B. Structure and Comparison with Zn- $\alpha_2$ -glycoprotein**

Sequence analysis of both the human and mouse LMF material revealed that it comprised a polypeptide chain having an N-terminus blocked  
 20 by a pyroglutamate residue. Treatment with HCl or pyroglutamate aminopeptidase to remove this residue, or cleavage with chymotrypsin, produced peptides that showed homology with human plasma Zn- $\alpha_2$ -glycoprotein in residues 2-6, 55-79 and 146-167 (see Araki *et al.*, reference 4). Purified human and mouse LMF also comigrated with Zn- $\alpha_2$ -glycoprotein  
 25 when electrophoresed on 15% SDS-PAGE as illustrated in FIGURE 4 in which lane 2 shows the banding pattern obtained using authentic human Zn- $\alpha_2$ -glycoprotein (prepared as described in reference 8). The purified human LMF

and human Zn- $\alpha_2$ -glycoprotein also had the same molecular weight (84,000) on 10% non-denaturing PAGE (see lanes 3 and 2 respectively in FIGURE 5). Using SDS-PAGE for detection of carbohydrate, both human and mouse materials stained heavily as did also authentic human Zn- $\alpha_2$ -glycoprotein. This is illustrated in FIGURE 6 in which lane 1 shows the effect of human plasma Zn- $\alpha_2$ -glycoprotein; lane 2 the effect of human LMF; lanes 3 and 4 the results with mouse LMF; lane 5 the result with transferrin (positive control); lane 6 the result with creatinase (negative control). The gel was stained for carbohydrate using the DIG glycan detection kit according to the manufacturer's instructions.

It was also found that a polyclonal antibody raised against authentic human plasma Zn- $\alpha_2$ -glycoprotein was capable of detection of human LMF on immunoblots, as shown in FIGURE 7, and of neutralisation of *in vitro* lipid mobilizing activity of the human, but not the mouse material. The latter is indicated in Table 4, and an explanation of this observation may lie in the fact that mouse Zn- $\alpha_2$ -glycoprotein has been shown to exhibit only 58.6% identity in amino acid sequence with the human counterpart (see reference 7).

FIGURE 8 shows the effect of  $\alpha$ -chymotrypsin on authentic human plasma Zn- $\alpha_2$ -glycoprotein and LMF. Lane 1 shows molecular weight markers; lane 2 shows human plasma Zn- $\alpha_2$ -glycoprotein; lane 3 shows human LMF; lane 4 shows the result of Zn- $\alpha_2$ -glycoprotein +  $\alpha$ -chymotrypsin; lane 5 represents human LMF +  $\alpha$ -chymotrypsin; and lane 6 is  $\alpha$ -chymotrypsin alone (control). Proteins were electrophoresed on 15% SDS-PAGE and stained with Coomassie brilliant blue. Both human plasma Zn- $\alpha_2$ -glycoprotein and the isolated and purified LMF showed the same chymotryptic cleavage fragments and chymotrypsin destroyed the *in vitro* biological activity of the LMF. Neither human plasma Zn- $\alpha_2$ -glycoprotein nor the human LMF contained the  $M_r$  24kDa proteolysis inducing factor (PIF) previously reported to co-purify with the LMF.

The expression of Zn- $\alpha_2$ -glycoprotein in various murine tumours and liver has also been quantitated by competitive PCR. Liver, being known to express Zn- $\alpha_2$ -glycoprotein, was used as a control for the tumours. Of the MAC tumours evaluated only the cachexia-inducing MAC16 was found to express Zn- $\alpha_2$ -glycoprotein.

### C. Biological activity

#### C.1 In vitro

The human LMF material isolated from the urine of cancer patients with weight loss as in Example 2 was tested at different doses for its lipolysis stimulating effect on freshly isolated murine epididymal adipocytes by measuring glycerol release using the lipolytic assay previously described. The test was also repeated using authentic human plasma Zn- $\alpha_2$ -glycoprotein and it was found that both the authentic Zn- $\alpha_2$ -glycoprotein and the human LMF material stimulated glycerol release with a comparable dose-response profile. This is illustrated in FIGURE 9 where diagram A shows the results for the human LMF at different concentrations and diagram B shows the results for the authentic human plasma Zn- $\alpha_2$ -glycoprotein.

Induction of lipolysis in adipocytes is thought to be mediated by an elevation of the intracellular mediator cyclic AMP, and in further tests it was found that incubation of murine adipocyte plasma membranes with the human LMF caused a stimulation of adenylate cyclase activity in a GTP-dependent process, with maximal stimulation occurring at 0.1 $\mu$ M GTP. Also, this activation of adenylate cyclase was found to be saturable with concentrations of LMF >5 $\mu$ g/assay. Using human plasma Zn- $\alpha_2$ -glycoprotein it was found that this also stimulated murine adipocyte plasma membrane adenylate cyclase in a GTP-dependent manner with maximal stimulation also at 0.1 $\mu$ M GTP. Again, this activation of adenylate cyclase by the Zn- $\alpha_2$ -glycoprotein was found to be saturable with concentrations >5 $\mu$ g/assay.

This data showing the similar effects and comparable dose-response profiles for LMF and Zn- $\alpha_2$ -glycoprotein, together with the ability of polyclonal antisera to Zn- $\alpha_2$ -glycoprotein to neutralise *in vitro* lipolysis by human LMF, the homology in amino acid sequence, and matching electrophoretic mobility, all provide strong evidence that the isolated and purified LMF is indeed Zn- $\alpha_2$ -glycoprotein. Although previous reports have shown that Zn- $\alpha_2$ -glycoprotein is an adhesive protein closely related to antigens of the major histocompatibility complex in amino acid sequence and domain structure, there have been no previous reports of a capacity of Zn- $\alpha_2$ -glycoprotein to induce lipolysis. Moreover, it has not previously been reported as being present in human urine. At present the mechanism by which a large acidic protein such as Zn- $\alpha_2$ -glycoprotein can stimulate adenylate cyclase is not known and is quite surprising since other known substances having a similar role are small and basic polypeptides.

## 15 C.2 *In vivo*

In order to determine if the purified LMF isolated from human urine as in Example 2 was capable of fat depletion *in vivo* a sample of this LMF material (8 $\mu$ g) was injected into male ex breeder NMRI mice over a 72h period. The LMF was injected at times 0, 17, 24, 41, 48, 62 and 72 hours and control mice were similarly injected with phosphate-buffered saline (PBS) at the same time points. The animals were killed at 89h and the body composition and serum metabolite levels were determined. As shown in FIGURE 10, there was a progressive decrease in body weight of the animals receiving LMF which was significantly lower than PBS treated controls within 41h of treatment. Changes in the body composition and serum metabolic levels are summarised in Table 5 and it will be seen that total body weight decreased by 3.6g during the overall 89h period of the experiment without change in food and water intake. Body composition analysis showed a large reduction (42%) in the body fat content of

mice receiving LMF, with a tendency to increase the non-fat mass although this did not reach a particularly significant level. In this connection some evidence has in fact been found indicating that the LMF may actually stimulate protein synthesis and thus increase muscle mass. Despite the fat mobilisation there were significant reductions in the serum concentrations of non-esterified fatty acids (NEFA), glycerol and glucose in mice receiving LMF.

As shown in FIGURE 11 and by the data in Table 6, intravenous administration to obese ob/ob mice of LMF (35 $\mu$ g) isolated from human urine produced a similar result. There was a decrease in total body weight which became significant within 24h of the first injection and remained below that of the control group over the 160h of the experiment. Body composition analysis showed weight loss to arise from a decrease in carcass fat (26.03  $\pm$  0.70g in controls and 21.09  $\pm$  0.99g in LMF treated animals) without an alteration in the water content or non-fat mass (see Table 6). Serum levels of glycerol and 3-hydroxybutyrate were significantly increased, while blood glucose levels were decreased and there was no effect on either triglyceride or NEFA levels.

#### D. Fragmentation

It was also established that the active 43kDa glycoprotein could be digested with trypsin to give a fragment of apparent molecular weight or relative molecular mass of 7kDa (as determined by gel filtration exclusion chromatography using a Sephadex<sup>TM</sup> 50 column) which still retains the biological activity of functioning as a lipid mobilising agent. This is illustrated by the results of a typical experiment depicted in Figure 12 in which samples of the isolated human LMF were incubated with trypsin at 37°C for different time periods and then analysed by Sephadex – 50 Gel Exclusion Chromatography and lipolytic assay. The results clearly indicate the presence of active fragments within the 2.5 to 2.7 fractions, the MW of these fragments, as deduced from a calibration curve, being 6kDa, 7kDa and 8kDa respectively as

shown on the figure. Positive and negative controls were performed, these being as follows: -ve = 0.027, +ve = 0.252.

### Therapeutic Use

Overall the results referred to in Section C.2 above in connection with the *in vivo* experiments confirmed an increased metabolism of fat and showed that in these model systems the isolated and purified human LMF produces a decrease in carcass weight specifically by depletion of adipose tissue. It is this particular ability of the human LMF, which is the same as or a close analogue of Zn- $\alpha_2$ -glycoprotein, to reduce adipose tissue without affecting muscle mass that most clearly demonstrates the potential for use of this material for the treatment of obesity in humans. As has been mentioned earlier, there is also some evidence indicating that this LMF material can actually stimulate protein synthesis and may therefore be useful for stimulating muscle development. Potentially, the material is also especially useful for treating humans with increased susceptibility to maturity onset diabetes such as can occur in cases of obesity.

For this therapeutic use, particularly for the controlled treatment of obesity in humans, either for medical reasons or cosmetic reasons, a therapeutically useful and non-toxic quantity of the essentially pure active substance, either a lipid mobilising factor isolated and purified substantially as herein described or the equivalent purified or synthetic Zn- $\alpha_2$ -glycoprotein, or material constituting a lipolytically active fragment derived from the latter, can be made up as a pharmaceutical formulation for administration in any suitable manner. Such formulations may be presented in unit dosage form and may comprise a pharmaceutical composition, prepared by any of the methods well known in the art of pharmacy, in which a preparation of the active lipolytic substance is combined in intimate association or admixture with any other suitable ingredient providing a compatible pharmaceutically acceptable carrier,

diluent or excipient. The formulations include those suitable for oral, rectal, topical and parenteral (including subcutaneous, intramuscular and intravenous) administration. For parenteral administration the formulations may comprise sterile liquid preparations of a predetermined amount of the active lipolytic substance contained in ampoules ready for use.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound in the form of a powder or granules; or as a suspension of the active compound in an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion of a draught. The active compound may also be presented as a bolus, electuary or paste.

The amount of the active compound which is required in order to be effective for treating obesity in mammals will of course vary and is ultimately at the discretion of the medical or veterinary practitioner treating the mammal in each particular case. The factors to be considered by such practitioner, e.g. a physician, include the route of administration, type of pharmaceutical formulation; the mammal's body weight, surface area, age and general condition.

## Diagnostic Applications

For diagnostic purposes, to detect the presence of a tumour in a human patient or to monitor the progress of a tumour under treatment, basically it is only necessary simply to take a sample of body fluid such as urine in which Zn- $\alpha_2$ -glycoprotein is not normally present in healthy individuals, and then to test this for the presence of the glycoprotein lipid mobilising agent or lipolytic factor (or equivalent Zn- $\alpha_2$ -glycoprotein) herein identified.

In practice, any convenient method may be used for detecting and/or



measuring this active lipid mobilising agent or lipolytic factor in the samples, and the apparatus and materials required may advantageously be packaged and supplied, together with appropriate practical instructions, in the form of self-contained diagnostic kits ready for immediate use. Particularly preferred  
5 diagnostic agents for detecting and/or measuring the active lipid mobilising or lipolytic factor in a convenient and reliable manner are biochemical reagents, such as monoclonal or polyclonal antibodies for example, capable of specifically recognising and binding to human Zn- $\alpha_2$ -glycoprotein and then being identifiable by, for example, a visual change or a special screening using  
10 an associated labelled marker molecule, or by any other suitable technique known in the art.

#### Monoclonal Antibodies

The production of monoclonal antibodies to the Zn- $\alpha_2$ -glycoprotein or Zn- $\alpha_2$ -glycoprotein like lipolytic factor of this invention can be achieved by the  
15 use of established conventional techniques commonly used in the art. Such monoclonal antibodies, once prepared, may be immobilized on suitable solid supports (in a column for example) and then used for affinity purification to prepare in a convenient manner any further quantities that may be required for testing of the purified active lipolytic factor from tumour extracts or body  
20 fluids.

It is envisaged, however, that another important use of such monoclonal antibodies, apart from their use as a diagnostic agent, will be a therapeutic application based on their properties as inhibitors or antagonists to the active lipolytic factor in human cancer patients and a consequent  
25 therapeutic value as agents for treating and suppressing the symptoms of cachexia and/or for preventing or reducing tumour growth. Thus, by virtue of this property, they can provide therapeutic agents and, more specifically, they can be used to make or manufacture a medical preparation or medicament for

the therapeutic treatment of cancer-associated cachexia and/or malignant tumours in mammals.

### Screening Applications

Apart from monoclonal antibodies as referred to above, it is likely that any agent which is antagonistic to, or an inhibitor of, the activity of this lipid mobilising or lipolytic factor of the present invention could have at least potential human therapeutic value. Hence, preparations of the purified, or at least partially purified, lipolytic factor (LMF) herein identified can be particularly useful, in accordance with a further aspect of the invention, for use in providing a convenient *in vitro* method of screening substances to find potential anti-cachectic and/or antitumour agents for therapeutic use. A typical example of this application using freshly prepared adipocytes from mouse epididymal adipose tissue is outlined below:

The experiments are set up as follows:

- 15           100µl purified LMF preparation + 1ml fat cells
- Compound to be screened + 1ml fat cells
- 100µl LMF preparation and compound + 1ml fat cells

Each compound is tested at increasing concentrations and all samples are prepared and processed in duplicate.

- 20           The samples are gassed for 2 min with 95% O<sub>2</sub>, 5% CO<sub>2</sub> mixture, mixed and incubated for 2 hour at 37°C. After 2 hour, 0.5ml from each sample is then assayed for glycerol content as hereinbefore described.

- 25           Compounds which appear to show some significant degree of inhibition can then be candidates for further evaluation.

In general, the inhibitory effect observed in such *in vitro* experiments can be expected to occur also *in vivo*, and it is anticipated that by using this screening method further antagonists or inhibitors will be found that will have useful therapeutic applications for the treatment of cancer-associated cachexia

and/or as antitumour agents.

#### MAC16 Cell Line and Purification

Although it is quite feasible for preparations containing useful amounts of the purified or partially purified active lipid mobilising or lipolytic factor to be produced as herein described from extracts of tumours, such as the MAC16 adenocarcinoma, grown *in vivo*, or from urine of cancer cachexia patients, or by synthetic methods, a more convenient and preferred alternative source may be provided by extracts of tumour tissue cell cultures, especially cultures of the MAC16 cell line previously referred to.

10       The cells of this cell line can be conveniently grown in RPMI 1640 media containing 10% foetal calf serum under an atmosphere of 10% CO<sub>2</sub> in air. When assayed in the adipocyte glycerol release assay method it has been found that such culture grown cells may release a greater amount of glycerol than do corresponding amounts of the tumour *in vivo*.

15       As will be seen, the invention presents a number of different aspects and it should be understood that it embraces within its scope all novel and inventive features and aspects herein disclosed, either explicitly or implicitly and either singly or in combination with one another. Also, many detail modifications are possible and, in particular, the scope of the invention is not to be construed as being limited by the illustrative example(s) or by the terms and expressions used herein merely in a descriptive or explanatory sense. It is also pointed out that insofar as the terms "lipid mobilising factor (LMF)", "lipid mobilising agent" and "lipolytic factor" are used in the present specification, these terms are generally to be regarded as being synonymous and have the same meaning.

25

Table 1. Purification of Lipid-Mobilizing Factor from MAC16 tumor

Purification stage	Total protein(mg)	Recovery (%)	Total activity ( $\mu\text{mol}/10^5$ adipocytes)	Recovery (%)	Specific activity ( $\mu\text{mol}/10^5$ adipocytes/mg protein)	Purification fold
Tumor homogenate	500	100	27		0.054	
Batch extraction on DEAE-cellulose	102	20.4	1.21	100	0.0119	1
Q-Sepharose	1.5	0.3	1.17	97	0.78	65
Superdex	0.61	0.1	1.12	93	1.84	154
HPLC DEAE-cellulose	0.12	0.02	1.02	84	8.5	714
HPLC Resource-iso	0.02	0.004	1	83	50	4201

Table 2. Purification of Lipid-Mobilizing Factor from Cancer Patient Urine

Purification stage	Total protein(mg)	Recovery (%)	Total activity ( $\mu\text{mol}/10^5$ adipocytes)	Recovery (%)	Specific activity ( $\mu\text{mol}/10^5$ adipocytes/mg protein)	Purification fold
80% $(\text{NH}_4)_2\text{SO}_4$ precipitation	210	100	78.4		0.37	
Q-Sepharose	0.2	0.1	1.19	100	5.95	1
HPLC DEAE-cellulose	0.036	0.017	1.15	97	31.9	5.4
HPLC Resource-iso	0.007	0.003	1.15	97	164.3	27.6

Table 3 Relationship between weight loss and appearance of LMF in urine

Patient number	Diagnosis	Weight loss (kg/month)	LMF
1.	Pancreatic cancer	1.6	+
2.	Cholangio carcinoma	4.2	+
3.	Gastric cancer	3.0	+
4.	Gastric cancer	2.2	-
5.	Pancreatic cancer	0	-
6.	Pancreatic cancer	4.6	+
7.	Pancreatic cancer	1.5	+
8.	Ovarian cancer	4.3	+
9.	Rectal cancer	0.7	+
10.	Periampullary cancer (recurrence)	0.3	+
11.	Colorectal cancer	0.5	-
12.	Hepatoma	1.4	+
13.	Pancreatic cancer	4.0	+
14.	Periampullary cancer	0.8	-
15.	Pancreatic cancer	1.3	+
16.	Normal	0	-

Table 4 Effect of a polyclonal antibody to human Zn  $\alpha_2$ -glycoprotein on human and mouse lipid mobilizing activity.

Addition	$\mu\text{mole glycerol}/10^5 \text{ adipocytes}/2\text{h}$	p (from factor alone)
Human LMF	$0.0062 \pm 0.0002$	
Human LMF + pAb	$0.0013 \pm 0.0012$	0.03
Mouse LMF	$0.0977 \pm 0.02$	
Mouse LMF + pAb	$0.1082 \pm 0.015$	NS

LMF (5 $\mu\text{g}$  human or 10 $\mu\text{g}$  mouse in PBS) were incubated overnight with agitation at 4°C with a polyclonal antibody (pAb) to human plasma Zn- $\alpha_2$ -glycoprotein (10 $\mu\text{g}$  in PBS) and the lipid mobilizing activity was determined as described in methods. Results are expressed as mean  $\pm$  SEM for three determinations and the experiment was repeated three times. Differences from values in the absence of the pAb were determined by Student's t-test.

Table 5 The effect of LMF isolated from human urine on body weight, body composition, food and water intake and serum metabolite levels in ex-breeder male NMRI mice

Parameter	Control	Treated	P
Final body weight (g)	35.5 ± 2.0	31.6 ± 2.2	0.01
Water (g)	22.0 ± 0.9	18.3 ± 0.8	NS
Non Fat (g)	7.7 ± 0.8	9.6 ± 0.9	NS
Fat (g)	5.9 ± 0.6	3.4 ± 0.4	0.05
Food intake (g/day)	8.0 ± 0.6	8.0 ± 0.2	NS
Water intake (ml/day)	4.5 ± 0.8	4.4 ± 0.4	NS
NEFA (mEq/l)	1.63 ± 0.09	0.95 ± 0.03	0.003
Glycerol (mM)	8.86 ± 0.51	6.73 ± 0.45	0.05
Triglyceride (mg/l)	0.323 ± 0.036	0.201 ± 0.027	NS
Glucose (mg/100ml)	223 ± 9	186 ± 0.08	0.02

Material was administered to mice according to the schedule in Fig. 10. Values represent the mean ± SEM for 5 mice per group. Differences from control values were determined by Student's t-test.



Table 6 The effect of human LMF on body weight, body composition, food and water intake and serum metabolite levels in ob/ob mice 160h after the first injection.

Parameter	Control	Treated	P
Initial body weight (g)	66.7 ± 4.2	67.9 ± 2.9	NS
Final body weight (g)	73.1 ± 4.3	69.5 ± 4.3	0.01
Water (%)	50.3 ± 0.5	53.7 ± 1.1	NS
Non Fat (%)	15.5 ± 0.9	17.4 ± 1.0	NS
Fat (%)	34.6 ± 0.6	30.6 ± 0.7	0.05
NEFA (mEq/l)	1.47 ± 0.12	1.45 ± 0.45	NS
Glycerol (mM)	2.51 ± 0.28	5.31 ± 0.45	0.02
Triglyceride (mg/l)	0.40 ± 0.05	0.49 ± 0.04	NS
Glucose (mg/100ml)	317 ± 11	260 ± 12	0.02
3-Hydroxybutyrate (mM)	0.30 ± 0.02	0.44 ± 0.01	0.001
Oxygen uptake ( $\mu$ l/mgBAT/h)	0.18 ± 0.06	0.55 ± 0.07	0.009

Material was administered to mice according to the schedule in Fig.11. Values represent the mean  $\pm$  SEM for 5 mice per group. Differences from control values were determined by Student's t-test.

## References

- (1) T. M. McDevitt *et al.*, (1995) "Purification and characterisation of a lipid-mobilising factor associated with cachexia-inducing tumours in mice and humans", *Cancer Research* 55, 1458-1463.
- 5 (2) P. Todorov *et al.* (1996), *Nature*, 379, 739-742.
- (3) Burgi and Schmid, (1961) "Preparation and properties of Zn- $\alpha_2$ -glycoprotein of normal human plasma" *J. Biol. Chem.* 236, 1066-1074.
- (4) T. Araki *et al.* (1988) "Complete amino acid sequence of human plasma Zn- $\alpha_2$ -glycoprotein and its homology to histocompatibility antigens" *Proc. Natl. Acad. Sci. U.S.A.*, 85, 679-683.
- 10 (5) H. Ueyama, *et al.* (1991) "Cloning and nucleotide sequence of a human Zn- $\alpha_2$ -glycoprotein cDNA and chromosomal assignment of its gene", *Biochem. Biophys. Res. Commun.* 177, 696-703.
- (6) H. Ueyama *et al.* (1993) "Molecular cloning and chromosomal assignment of the gene for human Zn- $\alpha_2$ -glycoprotein", *Biochemistry* 32, 12968-12976.
- 15 (7) H. Ueyama *et al.* (1994) "Structure and Expression of Rat and Mouse mRNAs for Zn- $\alpha_2$ -glycoprotein" *J. Biochem.*, 116, 677-681.
- (8) Ohkubo *et al.* (1988) "Purification and characterisation of human plasma Zn- $\alpha_2$ -glycoprotein" *Prep. Biochem.*, 18, 413-430.
- 20

- (9) Kohler *et al.*, (1976), *Eur. J. Immuno.*
- (10) D.M. Weir, "*Handbook of Experimental Immunology*", 3, 2<sup>nd</sup> ed. pp A2.10-A2.11, *Blackwell Scientific Publications, Oxford*, 1973.
- (11) M.Z. Atassi and A.F.S.A. Habeeb, "*Immuno-chemistry of Proteins*"  
 5 (M.Z. Atassi, ed), 2, pp 177-264, Plenum, New York, 1977.
- (12) Lanoyi and Nisonoff (1983), *J. Immuno. Meth.*, 56, 235.
- (13) Wieland, O. (1974), in "*Methods of Enzymatic Analysis*" (Ed. Bergmeyer, H.U.) Vol. 3. pp 1404-1409, Academic Press, N.Y.
- (14) S.A. Beck *et al.* (1987) "Production of lipolytic and proteolytic factors  
 10 by a murine tumour-producing cachexia in the host" *Cancer Res.* 47, 5919-5923 (reference 14).

0970443-05000  
 T02050-6370260

SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

10 (A) NAME: MICHAEL JOHN TISDALE  
 (B) STREET: Wellcott, Star Lane,  
 (C) CITY: Claverdon, Warwickshire  
 (E) COUNTRY: UNITED KINGDOM  
 (F) POSTAL CODE (ZIP): CV35 8LW

15 (A) NAME: PENIO TODOROV TODOROV  
 (B) STREET: 9 Mattock Way,  
 (C) CITY: Abingdon, Oxfordshire,  
 (E) COUNTRY: UNITED KINGDOM  
 (F) POSTAL CODE (ZIP): OX14 2PB

20 (ii) TITLE OF INVENTION: GLYCOPROTEINS HAVING LIPID MOBILISING  
 PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF

(iii) NUMBER OF SEQUENCES: 1

25 (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
 (B) COMPUTER: IBM PC compatible  
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

30

## (2) INFORMATION FOR SEQ ID NO: 1:

35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 277 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

45 (v) FRAGMENT TYPE: N-terminal

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Gln Glu Asn Gln Asp Gly Arg Tyr Ser Leu Thr Tyr Ile Tyr Thr Gly  
 1 5 10 15

55 Leu Ser Lys His Val Glu Asp Val Pro Ala Phe Gln Ala Leu Gly Ser  
 20 25 30

Leu Asn Asp Leu Gln Phe Phe Arg Tyr Asn Ser Lys Asp Arg Lys Ser  
 35 40 45

60 Gln Pro Met Gly Leu Trp Arg Gln Val Glu Gly Met Glu Asp Trp Lys  
 50 55 60

Glu Asp Ser Gln Leu Gln Lys Ala Arg Glu Asp Met Glu Thr Leu Lys

T02050" 05020400

	65		70		75		80									
	Asp	Ile	Val	Glu	Tyr	Tyr	Asn	Asp	Ser	Asn	Gly	Ser	His	Val	Leu	Gln
				85						90					95	
5	Gly	Arg	Phe	Gly	Cys	Glu	Ile	Glu	Asn	Asn	Arg	Ser	Ser	Gly	Ala	Phe
				100					105					110		
	Trp	Lys	Tyr	Tyr	Tyr	Asp	Gly	Lys	Asp	Tyr	Ile	Glu	Phe	Asn	Lys	Glu
10			115					120					125			
	Ile	Pro	Ala	Trp	Val	Pro	Phe	Asp	Pro	Ala	Ala	Gln	Ile	Thr	Lys	Gln
				130			135					140				
15	Lys	Trp	Glu	Ala	Glu	Pro	Val	Tyr	Val	Gln	Arg	Ala	Lys	Ala	Tyr	Leu
	145					150					155					160
	Glu	Glu	Glu	Cys	Pro	Ala	Thr	Leu	Arg	Lys	Tyr	Leu	Lys	Tyr	Ser	Lys
				165						170					175	
20	Asn	Ile	Leu	Asp	Arg	Gln	Asp	Pro	Pro	Ser	Val	Val	Val	Thr	Ser	His
				180					185					190		
	Gln	Ala	Pro	Gly	Glu	Lys	Lys	Lys	Leu	Lys	Cys	Leu	Ala	Tyr	Asp	Phe
25			195					200					205			
	Tyr	Pro	Gly	Lys	Ile	Asp	Val	His	Trp	Thr	Arg	Ala	Gly	Gln	Val	Gln
		210					215					220				
30	Glu	Pro	Glu	Leu	Arg	Gly	Asp	Val	Leu	His	Asn	Gly	Asn	Gly	Thr	Tyr
	225					230					235					240
	Gln	Ser	Trp	Val	Val	Val	Ala	Val	Pro	Pro	Gln	Asp	Thr	Ala	Pro	Tyr
				245						250					255	
35	Ser	Cys	His	Val	Gln	His	Ser	Ser	Leu	Ala	Gln	Pro	Leu	Val	Val	Pro
				260					265					270		
40	Trp	Glu	Ala	Ser	Xaa											
			275													

FOCUS 637626

CLAIMS

1. A biologically active lipid mobilising agent for use in therapy which has an apparent molecular mass  $M_r$  as determined by gel exclusion chromatography greater than 6.0 kDa, and which is capable of inducing lipolysis in mammalian adipocytes, characterised in that it has the properties and characteristics of a Zn- $\alpha_2$ -glycoprotein.
2. A purified biologically active lipid mobilising agent as claimed in Claim 1 for use in therapy characterised in that it is substantially free of proteolytic activity and consists essentially of a glycosylated polypeptide having an apparent relative molecular mass  $M_r$  of about 43kDa as determined by its electrophoretic mobility when subjected to 15% SDS-PAGE electrophoresis and having homology in amino acid sequence with the amino acid sequence (SEQ ID No: 1) of human plasma Zn- $\alpha_2$ -glycoprotein.
3. A lipid mobilising agent as claimed in Claim 2 further characterised in that it is obtainable by a process that includes sequential steps of subjecting biological material to ion exchange chromatography, exclusion chromatography, and then to hydrophobic interaction chromatography, said biological material being urine from a cancer cachexia patient or an extract of a culture of a MAC16 tumour cell line deposited under the provisions of the Budapest Treaty in the European Collection Of Animal Cell Cultures (ECACC) under an Accession No. 89030816.
4. A biologically active lipid mobilising agent as claimed in Claim 1 for therapeutic use which is a glycosylated polypeptide wherein the polypeptide moiety is selected from one of the following groups:
- a polypeptide having the amino acid sequence of a Zn- $\alpha_2$ -glycoprotein;
  - a polypeptide which in respect to (a) is deficient in one or more

amino acids that do not significantly affect the lipid mobilising or lipolytic activity;

c) a polypeptide in which in respect to (a) one or more amino acids are replaced by a different amino acid or acids that do not significantly affect the lipid mobilising or lipolytic activity;

d) a polypeptide in which in respect to (a) there is incorporated a plurality of additional amino acids which do not interfere with the biological lipolytic activity.

5. A biologically active lipid mobilising agent for use in therapy as claimed in Claim 1 consisting essentially of a glycoprotein that has a polypeptide amino acid sequence homologous with the amino acid sequence (SEQ ID No: 1) of human plasma Zn- $\alpha_2$ -glycoprotein, or with a variant thereof which is modified by minor additions, deletions, or substitutions that do not substantially affect its lipid mobilising activity in biological systems.

6. A lipid mobilising agent for use in therapy as claimed in Claim 4 or 5 further characterised in that it has an apparent relative molecular mass  $M_r$  of about 43kDa as determined by its electrophoretic mobility when subjected to 15% SDS-PAGE electrophoresis.

7. A lipid mobilising agent for use in therapy as claimed in any one of Claims 1 to 6 further characterised in that when subjected to digestion with chymotrypsin its lipid mobilising properties are destroyed.

8. A lipid mobilising agent for use in therapy as claimed in any one of Claims 1 to 7 further characterised in that it has the potential *in vitro* to stimulate adenylate cyclase activity in a guanine triphosphate (GTP) dependent process upon incubation with murine adipocyte plasma membranes.

9. A lipid mobilising agent for use in therapy as claimed in any one of Claims 1 to 8 further characterised in that it has substantially the same

immunological properties as human Zn- $\alpha_2$ -glycoprotein.

10. A biologically active lipid mobilising agent for use in therapy which is capable of inducing lipolysis in mammalian adipocytes characterised in that it has an apparent molecular mass  $M_r$  as determined by gel exclusion chromatograph greater than 6.0kDa and is obtainable by subjecting the lipid mobilising agent claimed in any one of the preceding claims to fragmentation by enzymatic degradation.

11. A biologically active lipid mobilising agent as claimed in Claim 10 for use in therapy that is a fragment of a glycoprotein or glycosylated polypeptide which is a component of the lipid mobilising agent claimed in any one of Claims 1 to 9 produced by digesting the latter with trypsin

12. A lipid mobilising agent for use in therapy as claimed in any one of the preceding claims further characterised in that it is substantially free of proteolytic activity.

13. A lipid mobilising agent for use in therapy as claimed in any one of the preceding claims further characterised in that the polypeptide chain of the polypeptide component has an N-terminus blocked by a pyroglutamate residue.

14. A lipid mobilising agent for use in therapy as claimed in any one of the preceding claims further characterised in that the lipid mobilising activity is destroyed by periodate treatment.

15. Use of a lipid mobilising agent as claimed in any of the preceding claims for the manufacture of a medicament useful in human medicine for treating conditions of overweight or obesity and/or for stimulating muscle development.

16. A method of isolating and purifying a lipid mobilising agent having the properties and characteristics of a Zn- $\alpha_2$ -glycoprotein, said method comprising subjecting an extract of a cachexia-inducing tumour or of a culture of a



cachexia-inducing tumour cell line, or a sample of urine or other body fluid of a mammal bearing a cachexia-inducing tumour, to a combination of ion exchange, gel filtration size exclusion chromatography, and hydrophobic interaction chromatography, and recovering a single product or molecular species having an apparent relative molecular mass of 43kDa, as determined by 15% SDS-PAGE electrophoresis, which is substantially free of proteolytic activity.

17. A pharmaceutical composition for use in treating mammals, said composition containing as the active constituent an effective therapeutic amount of a lipid mobilising agent as claimed in any one of Claims 1 to 14, together with a pharmaceutically acceptable carrier, diluent or excipient.

18. A pharmaceutical composition as claimed in Claim 17 which is an injectable formulation incorporating a carrier in the form of a pharmaceutically acceptable injection vehicle.

19. A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a lipid mobilising agent as claimed in any one of Claims 1 to 14.

20. A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a glycoprotein identical to or homologous with human Zn- $\alpha$ 2-glycoprotein, or an effective lipolytically active fragment thereof which has an apparent molecular mass Mr as determined by gel exclusion chromatography that is greater than 6.0kDa, substantially free of any proteolytic activity.

21. A diagnostic method for detecting the presence of a tumour in a mammal and/or for monitoring the progress of treatment of such a tumour, said

method comprising taking from said mammal a sample of urine, blood serum or other body fluid and testing to detect the presence of and/or to measure the amount therein of Zn- $\alpha_2$ -glycoprotein.

22. A diagnostic method as claimed in Claim 21 wherein the testing is carried out by use of a biochemical reagent capable of specifically recognising and binding to Zn- $\alpha_2$ -glycoprotein.

23. A diagnostic method as claimed in Claim 22 wherein the biochemical reagent is a monoclonal or polyclonal antibody.

24. A diagnostic method as claimed in any one of Claims 21 to 23 further characterised in that it is applied to a sample of urine.

25. A diagnostic kit for carrying out the method of Claim 21 or 22, said kit comprising a receptacle for receiving the sample of body fluid, a biochemical reagent for detecting Zn- $\alpha_2$ -glycoprotein, and instructions for use of said kit.

26. Use of a lipid mobilising agent as defined in any one of Claims 1 to 14 for producing antibodies for use as a diagnostic detecting agent for use in therapy as inhibitors or antagonists to the lipid mobilising agent causing cachexia in cancer patients.

27. Use of a preparation of antibodies for the manufacture of a medical preparation or medicament for the treatment of cachexia-associated cancer and/or tumours, wherein said antibodies are capable of specifically recognising and binding to the lipid mobilising agent claimed in any one of Claims 1 to 14.

28. Use as claimed in Claim 27 of a preparation of antibodies wherein the antibodies are monoclonal antibodies.

29. Use of a lipid mobilising agent as defined in any one of Claims 1 to 14 for screening and identifying and/or for carrying out investigations of possible lipolytic activity inhibiting agents having potential as anti-cachectic or antitumour therapeutic agents.

30. Use as claimed in Claim 29 wherein samples of possible antagonists to, or inhibitors of, the activity of said lipid mobilising agent are added to preparations of said lipid mobilising agent, followed by incubation *in vitro* with a preparation of adipocytes and assaying to determine the level of lipolytic activity relative to that of a control sample.
- 5

## FIG. 1

Gln Glu Asn Gln Asp Gly Arg Tyr Ser Leu Thr  
Tyr Ile Tyr Thr Gly Leu Ser Lys His Val Glu  
Asp Val Pro Ala Phe Gln Ala Leu Gly Ser Leu  
Asn Asp Leu Gln Phe Phe Arg Tyr Asn Ser Lys  
Asp Arg Lys Ser Gln Pro Met Gly Leu Trp Arg  
Gln Val Glu Gly Met Glu Asp Trp Lys Glu Asp  
Ser Gln Leu Gln Lys Ala Arg Glu Asp Met Glu  
Thr Leu Lys Asp Ile Val Glu Tyr Tyr Asn Asp  
Ser Asn Gly Ser His Val Leu Gln Gly Arg Phe  
Gly Cys Glu Ile Glu Asn Asn Arg Ser Ser Gly  
Ala Phe Trp Lys Tyr Tyr Tyr Asp Gly Lys Asp  
Tyr Ile Glu Phe Asn Lys Glu Ile Pro Ala Trp  
Val Pro Phe Asp Pro Ala Ala Gln Ile Thr Lys  
Gln Lys Trp Glu Ala Glu Pro Val Tyr Val Gln  
Arg Ala Lys Ala Tyr Leu Glu Glu Glu Cys Pro  
Ala Thr Leu Arg Lys Tyr Leu Lys Tyr Ser Lys  
Asn Ile Leu Asp Arg Gln Asp Pro Pro Ser Val  
Val Val Thr Ser His Gln Ala Pro Gly Glu Lys  
Lys Lys Leu Lys Cys Leu Ala Tyr Asp Phe Tyr  
Pro Gly Lys Ile Asp Val His Trp Thr Arg Ala  
Gly Gln Val Gln Glu Pro Glu Leu Arg Gly Asp  
Val Leu His Asn Gly Asn Gly Thr Tyr Gln Ser  
Trp Val Val Val Ala Val Pro Pro Gln Asp Thr  
Ala Pro Tyr Ser Cys His Val Gln His Ser Ser  
Leu Ala Gln Pro Leu Val Val Pro Trp Glu Ala  
Ser COOH

09701463-050201

FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6






FIG. 7






FIG. 8




7/10

FIG. 9




8/10

FIG. 10




9/10

FIG. 11



10/10



As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF

the specification of which (CHECK applicable BOX(ES))

X -> [ ] is attached hereto.  
BOX(ES) -> [X] was filed on November 29, 2000 as U.S. Application No 09/701,463  
-> [X] was filed as PCT International Application No PCT/GB99/01509 on 1 June 1999  
-> and (if U.S. or PCT application amended) was amended on 7 July 2000

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application.

PRIOR FOREIGN APPLICATION(S)		Date first Laid- open or Published	Date Patented or Granted	Priority Claimed Yes No
Number	Country	Day/MONTH/Year Filed		
9811465.5	U.K.	29 May 1998		X
PCT/GB99/01509 PCT		1 June 1999	9 December 1999	X

I hereby claim domestic priority benefit under 35 U.S.C. 119/120/365 of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application.

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S)		Status	Priority Claimed Yes No
Application No (series code/serial no.)	Day/MONTH/Year Filed	pending, abandoned, patented	
PCT/GB99/01509	1 June 1999	Pending	X

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Madison & Sutro LLP, Intellectual Property Group, 1100 New York Avenue, N.W., Ninth Floor, East Tower, Washington, D.C. 20005-3918, telephone number (202) 861-3000 (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete names/numbers below of persons no longer with their firm and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or a below attorney in writing to the contrary.

Paul N. Kokulis	16773	George M. Sirilla	18221	G Paul Edgell	24238	Richard H. Zaitlen	27248
Raymond F. Lippitt	17519	Donald J. Bird	25323	Lynn E. Eccleston	35861	Roger R. Wise	31204
G. Lloyd Knight	17698	Peter W. Gowdey	25872	David A. Jakopin	32995	Jay M. Finkelstein	21082
Carl G. Love	18781	Dale S. Lazar	28872	Mark G. Paulson	30793	Anita M. Kirkpatrick	32617
Edgar H. Martin	20534	Glenn J. Perry	28458	Timothy J. Klima	34852	Michael R. Dzwonczyk	36787
William K. West, Jr.	22057	Kendrew H. Colton	30368	Stephen C. Glazier	31361		
Kevin E. Joyce	20508	Paul E. White, Jr	32011	Paul F. McQuade	31542		
David W. Brinkman	20817	Michelle N. Lester	32331	Ruth N. Morduch	31044		

1. INVENTOR'S SIGNATURE: M. Tisdale Date 7.12.00

Inventor's Name (typed) MICHAEL J TISDALE UNITED KINGDOM  
Residence (City) WARWICKSHIRE (State/Foreign Country) UNITED KINGDOM  
Post Office Address (Include Zip Code) Wellcote, Star Lane, Claverdon, Warwickshire CV35 8LW, U.K. GBX

2. INVENTOR'S SIGNATURE: Penio Todorov Date 8.12.00

Inventor's Name (typed) PENIO T TODOROV UNITED KINGDOM  
Residence (City) OXFORDSHIRE (State/Foreign Country) UNITED KINGDOM  
Post Office Address (Include Zip Code) 9 Mattock Way, Abingdon, Oxfordshire OX14 2PB, U.K. GBX

3. INVENTOR'S SIGNATURE: \_\_\_\_\_ Date \_\_\_\_\_

Inventor's Name (typed) \_\_\_\_\_  
Residence (City) \_\_\_\_\_ (State/Foreign Country) \_\_\_\_\_  
Post Office Address (Include Zip Code) \_\_\_\_\_

(FOR ADDITIONAL INVENTORS, check box [ ] and attach sheet (PAT-116 2) for same information for each re signature, name, date, citizenship, residence and address.)

## SEQUENCE LISTING

<110> TISDALE, MICHAEL JOHN  
TODOROV, PENIO TODOROV

<120> GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND  
THERAPEUTIC APPLICATIONS THEREOF

<130> 040432-0275915

<140> 09/701,463

<141> 2001-05-02

<150> PCT/GB99/01509

<151> 1999-06-01

<150> GB 9811465.5

<151> 1998-05-29

<160> 1

<170> PatentIn Ver. 2.1

<210> 1

<211> 276

<212> PRT

<213> Homo sapiens

<400> 1

Gln Glu Asn Gln Asp Gly Arg Tyr Ser Leu Thr Tyr Ile Tyr Thr Gly  
1 5 10 15

Leu Ser Lys His Val Glu Asp Val Pro Ala Phe Gln Ala Leu Gly Ser  
20 25 30

Leu Asn Asp Leu Gln Phe Phe Arg Tyr Asn Ser Lys Asp Arg Lys Ser  
35 40 45

Gln Pro Met Gly Leu Trp Arg Gln Val Glu Gly Met Glu Asp Trp Lys  
50 55 60

Glu Asp Ser Gln Leu Gln Lys Ala Arg Glu Asp Met Glu Thr Leu Lys  
65 70 75 80

Asp Ile Val Glu Tyr Tyr Asn Asp Ser Asn Gly Ser His Val Leu Gln  
85 90 95

Gly Arg Phe Gly Cys Glu Ile Glu Asn Asn Arg Ser Ser Gly Ala Phe  
100 105 110

Trp Lys Tyr Tyr Tyr Asp Gly Lys Asp Tyr Ile Glu Phe Asn Lys Glu  
115 120 125

Ile Pro Ala Trp Val Pro Phe Asp Pro Ala Ala Gln Ile Thr Lys Gln  
130 135 140

Lys Trp Glu Ala Glu Pro Val Tyr Val Gln Arg Ala Lys Ala Tyr Leu  
145 150 155 160

Glu	Glu	Glu	Cys	Pro	Ala	Thr	Leu	Arg	Lys	Tyr	Leu	Lys	Tyr	Ser	Lys	165	170	175
Asn	Ile	Leu	Asp	Arg	Gln	Asp	Pro	Pro	Ser	Val	Val	Val	Thr	Ser	His	180	185	190
Gln	Ala	Pro	Gly	Glu	Lys	Lys	Lys	Leu	Lys	Cys	Leu	Ala	Tyr	Asp	Phe	195	200	205
Tyr	Pro	Gly	Lys	Ile	Asp	Val	His	Trp	Thr	Arg	Ala	Gly	Gln	Val	Gln	210	215	220
Glu	Pro	Glu	Leu	Arg	Gly	Asp	Val	Leu	His	Asn	Gly	Asn	Gly	Thr	Tyr	225	230	235
Gln	Ser	Trp	Val	Val	Val	Ala	Val	Pro	Pro	Gln	Asp	Thr	Ala	Pro	Tyr	245	250	255
Ser	Cys	His	Val	Gln	His	Ser	Ser	Leu	Ala	Gln	Pro	Leu	Val	Val	Pro	260	265	270
Trp	Glu	Ala	Ser													275		



# SEQUENCE LISTING

<110> TISDALE, MICHAEL, J

<120> GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND  
THERAPEUTIC APPLICATIONS THEREOF

<130> PCT/GB99/01509

<140> PCT/GB99/01509

<141> 1999-06-01

<150> GB 9811465.5

<151> 1998-05-29

<160> 1

<170> PatentIn Ver. 2.1

<210> 1

<211> 276

<212> PRT

<213> Homo sapiens

<300>

<301> Araki, Tomohiro, et al

<302> Complete amino acid sequence of human plasma  
Zn-a2-glycoprotein and its homology to  
histocompatibility antigens

<303> Proc. Natl. Acad. Sci. U.S.A.

<304> 85

<306> 679-683

<307> February 1998

<400> 1

Gln	Glu	Asn	Gln	Asp	Gly	Arg	Tyr	Ser	Leu	Thr	Tyr	Ile	Tyr	Thr	Gly
1				5					10					15	

Leu	Ser	Lys	His	Val	Glu	Asp	Val	Pro	Ala	Phe	Gln	Ala	Leu	Gly	Ser
			20					25					30		

Leu	Asn	Asp	Leu	Gln	Phe	Phe	Arg	Tyr	Asn	Ser	Lys	Asp	Arg	Lys	Ser
			35				40					45			

Gln	Pro	Met	Gly	Leu	Trp	Arg	Gln	Val	Glu	Gly	Met	Glu	Asp	Trp	Lys
			50			55					60				

Glu	Asp	Ser	Gln	Leu	Gln	Lys	Ala	Arg	Glu	Asp	Met	Glu	Thr	Leu	Lys
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

65		70		75		80									
Asp	Ile	Val	Glu	Tyr	Tyr	Asn	Asp	Ser	Asn	Gly	Ser	His	Val	Leu	Gln
			85						90					95	
Gly	Arg	Phe	Gly	Cys	Glu	Ile	Glu	Asn	Asn	Arg	Ser	Ser	Gly	Ala	Phe
			100					105					110		
Trp	Lys	Tyr	Tyr	Tyr	Asp	Gly	Lys	Asp	Tyr	Ile	Glu	Phe	Asn	Lys	Glu
		115					120					125			
Ile	Pro	Ala	Trp	Val	Pro	Phe	Asp	Pro	Ala	Ala	Gln	Ile	Thr	Lys	Gln
		130				135					140				
Lys	Trp	Glu	Ala	Glu	Pro	Val	Tyr	Val	Gln	Arg	Ala	Lys	Ala	Tyr	Leu
145					150					155					160
Glu	Glu	Glu	Cys	Pro	Ala	Thr	Leu	Arg	Lys	Tyr	Leu	Lys	Tyr	Ser	Lys
			165						170					175	
Asn	Ile	Leu	Asp	Arg	Gln	Asp	Pro	Pro	Ser	Val	Val	Val	Thr	Ser	His
		180						185						190	
Gln	Ala	Pro	Gly	Glu	Lys	Lys	Lys	Leu	Lys	Cys	Leu	Ala	Tyr	Asp	Phe
		195					200					205			
Tyr	Pro	Gly	Lys	Ile	Asp	Val	His	Trp	Thr	Arg	Ala	Gly	Gln	Val	Gln
		210					215				220				
Glu	Pro	Glu	Leu	Arg	Gly	Asp	Val	Leu	His	Asn	Gly	Asn	Gly	Thr	Tyr
225					230					235					240
Gln	Ser	Trp	Val	Val	Val	Ala	Val	Pro	Pro	Gln	Asp	Thr	Ala	Pro	Tyr
			245						250					255	
Ser	Cys	His	Val	Gln	His	Ser	Ser	Leu	Ala	Gln	Pro	Leu	Val	Val	Pro
		260						265					270		
Trp	Glu	Ala	Ser												
		275													